About this transcript: This is a full AI-generated transcript of Senate Judiciary Committee Considers Religious Freedom Bill and Judicial Nominations from NTD, published November 17, 2026. The transcript contains 20,569 words with timestamps and was generated using Whisper AI.
"This agenda, we have 14 nominations and one bill. We'll vote on three district court nominees, Robert Long, Peter Ransfield, Jesus Oceto. We'll also vote on several other nominees, Stephen Husk, U.S. Parole Commission, Samuel Lee, Gretchen Shepard, Roger Traster, four U.S. attorneys, and now four..."
[0:00] This agenda, we have 14 nominations and one bill.
[0:05] We'll vote on three district court nominees, Robert Long, Peter Ransfield, Jesus Oceto.
[0:15] We'll also vote on several other nominees, Stephen Husk, U.S. Parole Commission,
[0:23] Samuel Lee, Gretchen Shepard, Roger Traster, four U.S. attorneys,
[0:32] and now four U.S. Marshals, Reed Cresswell, James Edge, Christopher Inovat, and James Jackson.
[0:48] The remaining nominations and the bill will be held over for future consideration.
[0:54] We have a lot to get done on today's agenda.
[0:57] I understand that there's disagreement about the scope of the protections that would be afforded
[1:06] in the Right to Worship bill.
[1:08] It's been held over so that Ranking Member Durbin and Senator Cruz's office can continue
[1:15] to work through those differences, but I'm hopeful that we can vote on it at an upcoming markup.
[1:23] As for today's votes, I'd note that the committee remains steadfast in its commitment to the
[1:30] American people.
[1:32] As chairman, I've tried to work diligently to ensure that high-caliber nominees get processed
[1:39] and advanced efficiently, and I thank my colleagues for helping accomplish that goal.
[1:46] Federal judges, U.S. attorneys, and U.S. Marshals, among the most important business of this committee
[1:55] and the committee's review of their qualifications, they're the backbone of our justice system,
[2:04] and the American people need folks in these roles to keep the wheels of justice rolling.
[2:11] Today's judicial nominees are highly qualified.
[2:15] Their track record demonstrates a commitment to the Constitution and the rule of law,
[2:20] and I'm confident that they will preside over cases without fear or favor.
[2:26] I'm also pleased to have so many U.S. attorneys and U.S. Marshals on the agenda.
[2:36] These men and women have the experience and qualification to lead federal law enforcement
[2:40] in their respective jurisdictions, and I'm confident that they'll work hard to keep Americans safe.
[2:47] Senator Durbin.
[2:52] Thanks, Mr. Chairman.
[2:53] Observers of the Senate Judiciary Committee know we typically meet on Thursday mornings at 10 a.m.,
[2:58] as specified in our rules, yet here we are, second week in a row,
[3:04] meeting on Tuesday at 9 a.m., prior to a previously scheduled hearing on a different topic.
[3:10] What's going on?
[3:12] Republicans are in a mad scramble to confirm as many judicial nominees as possible
[3:16] before the Democrats take majority control of the Senate in January.
[3:20] My Republican colonies argue this is business as usual.
[3:25] In fact, the majority is violating longstanding bipartisan committee norms
[3:30] to jam through nominees in the Senate in this lame-duck session.
[3:34] Republicans claim they aren't acting any differently than Democrats did when we were in the majority.
[3:43] Simply not true.
[3:45] The reality is these practices have been followed for years by Republicans and Democrats
[3:50] to ensure both sides have adequate time to review prospective lifetime nominees to the federal bench
[3:58] to fulfill our advice and consent responsibility under the Constitution.
[4:02] On the rare occasions that we deviated from these rules,
[4:08] it has only been with the consent of the minority.
[4:12] There is no consent to what we're doing now.
[4:15] It's just going forward.
[4:17] Consider the committee's longstanding 28-day rule.
[4:22] Since at least the George W. Bush administration,
[4:24] a committee does not hold a hearing on a nomination for a lifetime appointment to the court
[4:29] until at least 28 days after we receive the nominee's Senate Judiciary Questionnaire.
[4:36] But tomorrow, the committee is planning to give a hearing to three nominees
[4:41] whose questionnaires were received 7 days ago, 10 days ago, 14 days ago, respectively.
[4:51] The only exceptions to the 28-day rule in recent history are Supreme Court nominations.
[4:58] These exceptions we're witnessing applied to all court nominations.
[5:01] Republicans violated the 28-day rule to rush through Justice Barrett's nomination before the 2020 election.
[5:09] That was the only time that happened before now.
[5:13] Then, when I was chair, I followed the precedent Republicans established for Supreme Court nominees
[5:18] when it came to Ketanji Brown-Jackson.
[5:20] But contrary to what's been said by the chairman,
[5:24] I followed the 28-day rule for every single one of the 234 lower court nominees confirmed during the Biden administration.
[5:35] In my four years as chair, I followed committee rules.
[5:40] Precedents set by my Republican predecessors.
[5:44] For example, Chairman Grassley eliminated the blue slip for circuit court nominees.
[5:48] We followed his lead.
[5:50] I simply continued that practice as chair.
[5:52] For four years, I listened to Republicans' committee even complain
[5:56] they no longer had a blue slip veto over a circuit court nominee from their home state.
[6:02] But the new standard established by our current chairman was followed.
[6:07] The chairman is within his rights to schedule any nominee he would like for a hearing.
[6:12] But I want to warn my Republican colleagues.
[6:14] You'll regret changing the 28-day rule to a 7-day rule.
[6:18] This is the same committee, incidentally, which decided the American Bar Association
[6:24] was no longer welcome to review nominees.
[6:28] After all of the years of the ABA grading these nominees as qualified, unqualified,
[6:35] it turns out that the Republicans don't want to hear from them anymore.
[6:38] Could it possibly be because nine of President Trump's nominees in his first term
[6:44] were found unqualified by the ABA?
[6:46] I think perhaps it does.
[6:49] Remember this day when a future Democratic chair moves judicial nominees through the committee,
[6:53] with one week, for you to review their background and qualifications for a lifetime appointment.
[6:58] I know you won't be happy with that.
[7:00] Why are you doing it?
[7:01] Simple.
[7:02] Under the 28-day rule nominees put forward after the election
[7:05] can't be confirmed before the end of the Congress.
[7:08] So Republicans decided to change the rule.
[7:11] In fact, break the rule.
[7:13] And to hell with the minority's consent.
[7:16] Republicans are trying to justify these steps by claiming
[7:18] that Democrats plan to shut down judicial nominations once we take the majority.
[7:24] They cannot cite any statement by a Senate Democrat to support that claim.
[7:30] And this complaint is especially rich coming from the Republican side,
[7:34] who engaged in unprecedented obstruction the last time there was a Democratic president
[7:39] and a Republican Senate.
[7:41] In 2015 and 2016, under the leadership of then-majority leader McConnell
[7:47] and the current chairman,
[7:49] the Senate confirmed 22 of President Obama's judicial nominees.
[7:55] 2015, 2016, 22.
[7:58] That was the fewest confirmations in Congress since 1952,
[8:03] a decision made by the Republican majority to just as they know.
[8:06] By comparison, during the last two years of George W. Bush's presidency,
[8:11] the Democratic-controlled presidency confirmed 68 judicial nominations.
[8:16] Republicans refused to allow any consideration of Merrick Garland,
[8:20] if you'll remember, nominee by President Obama to the Supreme Court.
[8:24] Never before in history had the Senate denied a Supreme Court nominee a hearing and a vote.
[8:30] Senate Republicans turned obstruction of judicial nominees
[8:33] into an art form under President Obama.
[8:36] So forgive me if I shed no tears
[8:39] when Republicans complain about Democrats refusing to rubber-stamp
[8:42] unqualified MAGA nominees once we take the majority in January.
[8:48] I yield.
[8:49] Now listen.
[8:50] Chairman, may I have a comment?
[8:52] After I get done speaking.
[8:54] That's fine.
[8:56] Now listen so I can show you that we've done more thorough research
[9:00] than you have on precedent.
[9:02] I addressed this issue just last week,
[9:05] and evidently you've got a short memory.
[9:07] Democrats have undertaken unprecedented levels of obstruction
[9:12] to stall President Trump's nominees throughout his second administration,
[9:17] and they've publicly made clear that they're planning to block
[9:20] Trump-nominated judges next Congress.
[9:25] Senate Minority Leader Schumer told the press that blocking lower court judges was,
[9:31] quote,
[9:32] one of the reasons that we want to do everything we can to take back the Senate, end quote.
[9:37] One of my Democratic colleagues on this committee advocated for a, quote,
[9:42] hard reset on nomination process next Congress.
[9:47] And another said, that's end of quote.
[9:49] And another one said, quote,
[9:51] I think it's slim to none that we would support nominees from this administration, end of quote.
[9:58] It's readily apparent, then, that Democrats plan to block judges next Congress.
[10:05] This has created an exigent circumstance with the limited time remaining on the Senate counter.
[10:13] So I'm working hard to get judges confirmed quickly during this lame duck session.
[10:19] After all, the Democrats did the same thing in 2024 when they were about to lose control of the Senate.
[10:25] They moved ahead and confirmed 22 federal judges during the lame duck.
[10:29] But now my Democratic colleagues criticize this chairman for following suit.
[10:35] I explained last week that what I'm doing isn't anything new.
[10:40] The chairman has always had discretion to set committee's hearing schedule.
[10:44] In response, the ranking members claimed that there's difference.
[10:49] He said the minority consent was always given before the chairman has waived committee norms in the past.
[10:57] That is incorrect.
[10:59] On multiple occasions, the chairman has permitted a district court nominee to sit fewer than 28 days after receipt of the Senate questionnaire.
[11:12] And the chairman from both parties have done this for higher court nominations over objections from the minority.
[11:20] Additionally, nomination hearings have been held on a compressed time frame
[11:27] at least three dozen times since Obama administration.
[11:31] On at least one set of those occasions in the 116th Congress, the truncated schedule was set without minority consent.
[11:43] Regardless, I'm not going to entertain complaints about minority consent
[11:47] when the same courtesies that I've offered in the past aren't reciprocated now.
[11:52] I remind my colleagues that nearly 70% of the truncated hearings happened during when the Democrats were in the majority.
[12:02] That includes four hearings over a span of four weeks in the 113th Congress when I was ranking member.
[12:09] At the final hearing in that stretch, I noted the compressed time frame.
[12:15] And I said this, cooperation that we Republicans have shown,
[12:18] and I as ranking member trying to work with the chairman, end of quote.
[12:24] To be clear, truncated hearings occurred 16 times while I served as ranking member.
[12:31] My consent was a courtesy based on the bipartisan work of the committee has long enjoyed.
[12:38] As ranking member, I extended that courtesy for truncated hearings more than any other Republican or Democrat member of this committee in the modern era.
[12:48] And the same courtesies haven't been reciprocated.
[12:52] And as is often said in this committee, we're not going to have one set of rules for a Republican and another set for Democrats.
[13:04] So we're pressing forward.
[13:06] The federal judiciary can't function without judges filling these critical vacancies.
[13:11] And I'm not going to let the federal bench stagnate for several, next several years while the Democrats block two additional nominations.
[13:21] We're going to continue to process and review these nominations efficiently.
[13:26] And we're going to get them confirmed quickly while still have time.
[13:31] Senator Whitehouse.
[13:33] Thank you very much, Chairman.
[13:35] I'm no Carnac the Magnificent, but I think I can safely predict that in the next Congress, there are going to be calls from the Republican side for the majority to respect the rules and the norms and the traditions of this committee.
[13:54] So let me just go over some of what we've seen just in this past Congress.
[14:01] Committee members customarily are permitted to ask questions for the record and expect to have those questions answered and, frankly, answered timely.
[14:14] Over and over again, we have seen members of this committee file questions for the record that are completely ignored.
[14:20] Literally zero answers.
[14:24] And the majority was fine with that.
[14:26] We have seen pretty obvious lies told by administration witnesses in this committee, and they have been allowed to go unchallenged.
[14:35] And it's a little ironic because in some cases, they were from people who are trying to prosecute previous FBI directors for lies to Congress.
[14:48] So you'd think there'd be a pretty high bar around lies to Congress, but that has been allowed to go unchallenged.
[14:55] We have seen over and over again administration witnesses come in not ready to answer questions, but with a pre-prepared little insults list so that they can use usually flawed opposition research against members of this committee rather than answer our oversight questions.
[15:15] And that has been allowed to continue, and the majority has seemed fine with that.
[15:22] The confirmation responsibility of this committee is a pretty important one.
[15:25] The administration has come up with ways to put fake U.S. attorneys in without coming through this committee for confirmation.
[15:38] Over and over again, those decisions have been thrown out by courts.
[15:42] You'd think that this committee, of all, would want to defend its responsibilities and its authorities over confirming U.S. attorneys, and yet that has gone without complaint.
[15:51] We have seen preposterous privileges asserted here by witnesses with no challenge to that.
[15:58] The assertions of privilege, which violated even the Reagan memo on privileges, have been allowed to stand, and we've moved nominees forward, even though their standard questionnaires have been left incomplete.
[16:10] That's just a little bit of the backdrop from this Congress, and what I was hoping is that in this intervening lame duck period, we could begin to get a reset to a more normal committee procedure, more normal and respectful process.
[16:31] But I see no sign of that, in fact, right now, with these nominees, committee time and filing requirements are just being waved away.
[16:42] It is, to quote the chairman, we're not going to have one set of rules when Republicans are in charge and another set of rules when Democrats are in charge.
[16:51] At the end of the day, we're going to need to come together as a committee and decide if this committee wants to be a serious and responsible committee with serious and responsible rules that does the serious and responsible work we are supposed to be doing.
[17:04] But until that time, I just have to express my regret at the direction we have taken.
[17:09] We'll now turn to the nomination of Robert Wong to serve as judge, U.S. District Court, Middle District, Florida.
[17:18] Clerk will call the roll.
[17:19] Aye.
[17:21] Aye.
[17:35] Nope.
[17:37] Nope.
[17:37] No by proxy.
[17:40] No by proxy.
[17:41] No by proxy.
[17:45] No by proxy.
[17:47] No by proxy.
[17:49] No by proxy.
[17:50] Aye.
[17:53] Nomination will be favorably reported.
[17:59] We'll now turn to the nomination of Peter Mansfield to serve as a judge of the U.S. District Court, Eastern District, Louisiana.
[18:07] Clerk will call the roll.
[18:10] Aye.
[18:10] Nope.
[18:30] No by proxy.
[18:31] No by proxy.
[18:36] Aye by proxy.
[18:40] No by proxy.
[18:41] No by proxy.
[18:45] No by proxy.
[18:49] Aye.
[18:56] Favorably report Peter Mansfield as a result of that roll call vote will now go to A.S.
[19:02] Ossetti.
[19:03] Mr. President, or Mr. Chairman, I have a statement I'd like to make.
[19:08] Mr. Ossetti graduated from law school in 2016.
[19:10] We're getting younger and younger nominees.
[19:13] Remember, this is for a lifetime appointment to the federal bench.
[19:18] So you expect some experience.
[19:22] Even among the unqualified and inexperienced nominees put forward by the president, Mr. Ossetti stands out.
[19:29] Over the course of his career, he has attacked voting rights, reproductive rights, LGBTQ rights.
[19:36] Since last year, he has served as senior political appointee in the Civil Rights Division of Justice, known as the crown jewel of the Justice Department.
[19:47] During Mr. Ossetti's tenure, the Trump administration has decimated this division.
[19:53] More than 70 percent of the department's lawyers have been fired or forced out.
[19:58] And the division has abandoned much of its work enforcing civil rights laws to target Mr. Trump's enemies.
[20:06] Among other things, Mr. Ossetti took part in meetings investigating the 2020 elections in Fulton County, Georgia.
[20:14] More than five years after President Trump lost that election.
[20:17] A fact which nominees refuse to acknowledge when they appear before this committee.
[20:23] Mr. Ossetti has a history of moving in whichever way he thinks the political wind is blowing.
[20:28] In 2016, he rightly criticized the Supreme Court's decision in Shelby County that struck a major blow to the Voting Rights Act.
[20:37] But over the past two years, he joined the Trump administration's efforts to attack voting rights and undermine confidence in elections.
[20:45] Similarly, in 2020, he posted on social media several times in support of efforts, support of efforts to increase diversity in the legal profession.
[20:56] At one point, he wrote, we need more diversity in these institutions.
[21:02] But while working for the Trump Justice Department, he got religion.
[21:06] He has frequently attacked diversity and said, DEI will either die on its own or we will kill it.
[21:12] He's everywhere politically.
[21:14] Considering his record, I have my doubts as to whether Mr. Ossetti is able to be a neutral arbitrary on the federal court.
[21:22] He's going to have a lifetime to prove me wrong if this Republican majority rules.
[21:27] I yield the floor.
[21:28] Clerk will call the roll.
[21:31] Aye.
[21:32] Aye.
[21:47] Nope.
[21:49] Nope.
[21:50] No by proxy.
[21:51] No by proxy.
[21:55] No by proxy.
[21:56] Mr. Ossetti.
[21:57] No by proxy.
[21:58] No by proxy.
[22:00] No by proxy.
[22:02] No by proxy.
[22:04] Aye.
[22:08] Nomination will be favorably reported.
[22:15] Now we go to Stephen Husk.
[22:17] Stephen Husk to serve as commissioner on the U.S. call the roll.
[22:24] Aye.
[22:25] Aye by proxy.
[22:50] No.
[22:50] Aye by proxy.
[22:53] No by proxy.
[22:58] Proxy.
[23:11] No by proxy.
[23:14] No by proxy.
[23:15] Aye by proxy.
[23:16] Mr.
[23:21] Aye.
[23:22] The nomination will be favorably reported.
[23:29] Mr. Chairman, I ask to be recorded as present with my aye that I voted in person.
[23:36] You got that?
[23:39] Now we'll turn to Samuel Lee, U.S. Attorney, Eastern District of Tennessee.
[23:45] Clerk will call the roll.
[23:46] Mr. Chairman, may I say a word?
[23:48] Yes.
[23:48] I want to make it clear because it was raised yesterday by your leader.
[23:53] The issue requiring a roll call vote for U.S. attorney nominees is not a Democratic strategy.
[23:59] It is a strategy propagated by J.D. Vance when he was a member of the Senate.
[24:04] He decided that despite the fact that in Trump's first term, every one of the nominees save one
[24:10] went by voice vote, he wanted to require under Biden a roll call vote on each and every U.S.
[24:16] attorney nominee.
[24:18] Seven times I went to the floor and asked unanimous consent for him to decide otherwise.
[24:23] To give us the same courtesy under Biden we gave under Trump won.
[24:27] He refused seven times.
[24:29] That's the reason for these roll call votes.
[24:31] Clerk will call the roll.
[24:33] Aye.
[24:36] Aye.
[24:36] No by proxy.
[24:56] No by proxy.
[24:58] No by proxy.
[25:00] No by proxy.
[25:02] Aye.
[25:04] No by proxy.
[25:07] No by proxy.
[25:10] No by proxy.
[25:11] Aye.
[25:16] The nomination will be favorably reported.
[25:22] Now we go to Gretchen Shepard.
[25:26] Please call the roll.
[25:27] Aye.
[25:30] Kennedy.
[25:45] Ms. Graham.
[25:48] Aye.
[25:48] No by proxy.
[25:50] Ms. Colbert.
[25:51] No by proxy.
[25:52] No by proxy.
[25:54] No by proxy.
[25:55] Aye.
[25:57] No by proxy.
[26:02] No by proxy.
[26:05] No by proxy.
[26:06] No by proxy.
[26:11] Aye.
[26:11] The nomination will be favorably.
[26:17] Now we go to Robert Trisker to serve as U.S. attorney, Western District, Oklahoma.
[26:24] The clerk will call the roll.
[26:25] No by proxy.
[26:48] Aye.
[26:49] The nomination will be favorably reported.
[26:51] Now we go to James Edge, U.S. Marshal, Western District, North Carolina.
[27:19] The clerk will call the roll.
[27:42] No by proxy.
[27:44] Aye.
[27:44] Aye.
[27:44] Aye.
[27:44] Aye.
[27:44] Aye.
[27:44] Aye.
[27:44] Aye.
[27:44] Aye.
[27:45] Aye.
[27:47] Aye.
[27:48] Aye.
[27:49] Aye.
[27:50] Aye.
[27:52] Aye.
[27:52] Aye.
[27:54] Aye.
[27:55] Aye.
[27:59] Aye.
[27:59] Aye.
[28:01] Aye.
[28:02] Aye.
[28:07] Aye.
[28:08] Aye.
[28:08] Aye.
[28:09] Aye.
[28:11] Aye.
[28:12] Aye.
[28:13] Aye.
[28:14] Aye.
[28:14] Four me.
[28:20] Aye.
[28:20] Aye.
[28:20] The nomination will be favorably reported.
[28:22] Now we'll go to Reed Cresswell, U.S. Marshal, South Carolina.
[28:29] The clerk will call the roll.
[28:31] Aye.
[28:33] Aye.
[28:34] Aye.
[28:34] Aye.
[28:39] Mr. Kennedy.
[28:40] Blackburn.
[28:42] Mr. Schmidt.
[28:44] Mr. Schmidt.
[28:44] Aye.
[28:45] Mrs. Britt.
[28:45] Aye.
[28:46] Mrs. Mooney.
[28:47] Aye.
[28:47] Ms. Graham.
[28:49] Mr. Dervid.
[28:51] Aye.
[28:51] Aye.
[28:53] No by proxy.
[28:54] Ms. Kodrchard.
[28:55] Aye.
[28:56] Aye.
[28:58] Aye.
[28:58] Aye.
[29:00] Aye.
[29:01] Aye.
[29:01] Aye.
[29:01] Aye.
[29:03] Aye.
[29:03] proxy. No by proxy. No by proxy. Aye by proxy. Aye. The nomination will be favorably reported.
[29:23] Now we go to Christopher Inibet to be U.S. Marshal Middle District, Alabama. Clerk will call the roll.
[29:29] No by proxy. No by proxy. No by proxy. No by proxy. No by proxy. No by proxy. No by proxy. No by proxy.
[30:04] No by proxy. Aye. Mr. Chairman, I'd like to make a statement about the nominee we just considered.
[30:15] Yeah, please proceed. I'm troubled by. Let me announce this. Oh, sure. Go ahead.
[30:21] It will be reported. Go ahead. I'm deeply troubled by Mr. Inibet's law enforcement career. During his
[30:29] time as director of Alabama's State Bureau of Investigations, he repeatedly denied requests
[30:34] to release body-worn camera footage from police shootings. In 2023, a police officer claimed he
[30:41] shot and killed a black Alabama named Steve Perkins because Mr. Perkins aimed a weapon at him. Almost
[30:48] immediately, Mr. Inibet's agency issued a press release in support of the officer's statement.
[30:54] Yet, when the Perkins family asked to view the officer's body-worn camera footage, Mr. Inibet denied
[31:00] the request, claiming that disclosing the recording would affect an ongoing investigation. Months later,
[31:07] the officer who killed Mr. Perkins was charged with murder and other officers on the scene were later
[31:13] fired. In 2025, police officers shot an Alabama man in the back, killing him. When the man's family
[31:21] requested a private, supervised viewing of the footage, Mr. Inibet and his agency refused to let
[31:27] them see the video footage. This committee has held hearings on body-worn cameras, and there's bipartisan
[31:34] agreement that these cameras can enhance public trust in police. How can a body-worn camera be
[31:39] effective when people like Mr. Inibet blocked that footage from seeing the light of day? Mr. Inibet's
[31:45] record is so troubling, the National Urban League and the Urban League of Alabama issued a letter
[31:51] opposing his nomination, saying he has a long and painful history of state-sponsored violence against
[31:58] black people, especially by law enforcement officers. This is a man who is seeking to become the
[32:04] U.S. Marshal for the Middle District of Alabama. I listened to what they said. Mr. Inibet has a
[32:11] troubling record of excusing violence and suppressing information related to officer-involved shootings.
[32:17] That makes him fundamentally unfit in the view of the Urban League to handle the awesome
[32:22] responsibilities of this role. I'm sorry that this committee has decided to approve his nomination.
[32:27] Thank you. Clerk will call the roll on James Jackson, U.S. Marshal, Eastern District of Texas.
[32:36] Aye. Aye. Nope. No by proxy. No by proxy. No by proxy. No by proxy. No by proxy. No by proxy. No by proxy.
[33:05] No by proxy. No by proxy. Aye. The nomination will be favorably reported. Meeting will be adjourned.
[36:14] Prescription drug costs. Today we're examining questions that matter to every family. Why do prescription drug
[36:23] costs so much? How do we make them affordable? Needless to say, the prescription drug supply chain
[36:33] is very complicated. Manufacturers set list prices. Wholesalers and distributors move product. Pharmacy
[36:42] benefit managers set prices. Build formularies, process claims, and create pharmacy networks.
[36:52] Insurers and employers design the benefits. Pharmacies fill the prescriptions. Each one of these
[37:01] prescriptions affects the final cost. I said that wrong. Each one of these participants
[37:11] affect the final cost. However, when the transactions are hidden behind confidential contracts,
[37:18] rebates, fees, and payments to affiliated companies, patients and consumers have a hard time following
[37:28] the money. When companies are allowed to engage in anti-competitive and abusive tactics, drug prices
[37:36] remain high for patients. Last year, this committee advanced six bipartisan bills that address the high
[37:45] high cost of prescription drugs and the abusive practices that keep prices too high for too many American
[37:54] families. These bills will help make medications more affordable for patients. These bills address
[38:04] anti-competitive tactics in the pharmaceutical supply chain including opaque pharmacy benefit
[38:12] managers practices, product hopping, patent games, sham citizen petitions, pay for delay deals, and the need to
[38:25] strengthen collaboration in the drug patent process between the FDA and the patent office. I'm glad that the
[38:35] Senate unanimously passed one of these bills, the affordable prescription for patients act. We did that in July. It's time for the
[38:46] Senate to pass the five other bills that have been reported by this committee. Last year, this committee held a
[38:54] hearing focused specifically on PBMs. We learned that these entities originally existed to process pharmacy claims. Then they
[39:04] began negotiating prices and managing drug benefits. In recent years, PBMs role has continued to evolve. They now exercise
[39:17] significant power over what medications patients can access, how much the patient will pay, how much the pharmacy gets paid, and a lot of
[39:29] other transactions. My two-year bipartisan investigation into insulin price gouging cited by the FTC found that PBMs
[39:42] encourage drug makers to spike a drug list price in order to offer a greater rebate. This in a turn allows
[39:52] manufacturers to secure priority placement on covered meds all at the expense of the patient. For
[40:02] years, I press the Federal Trade Commission to study PBMs and their impact on competition and drug costs. I'm glad that
[40:13] the FTC listened and began their studies into PBMs now a long time ago, 2022. While the FTC's two interim staff
[40:24] reports are helpful, I'm eager to get their full report with legislative recommendations. Last month, I asked
[40:33] the FTC for the FTC for an update on when Congress will see that report. I also appreciate that FTC
[40:42] has issued two proposed consent orders with major PBMs. The enforcement of those settlements will need to be
[40:51] monitored to ensure that they benefit patients. While a report on PBM is crucial, we can address some
[41:03] anti-competitive behavior today. In February, Congress took some action on PBM reform in Medicare Part D
[41:13] and the private insurance market. I'm glad that the Department of Labor implemented its regulation last
[41:20] month. I look forward to the Centers for Medicare and Medicaid Services completing its regulatory work
[41:29] next year. I'm watching both regulations closely to ensure that they help patients and lower drug costs.
[41:38] These are good first steps, but more PBM reform is needed. I'm on record calling for more transparency
[41:46] and accountability in the PBM industry. That industry may try to argue that they've changed their ways
[41:54] and they're more accountable. This senator disagrees. PBMs are still too opaque and too powerful,
[42:05] while patients, pharmacies, and taxpayers are being hurt by these powerful drug middlemen. The effort to
[42:13] lower prescription drug costs is a very bipartisan issue. The Senate should also consider the Drug
[42:21] Prices Transparency Consumer Act. This bill is a priority for Senator Durbin and this senator. If a drug
[42:30] company can advertise a prescription drug directly to the public, it should disclose the product's price
[42:40] to the public as well. Sunlight gives patients information to ask better questions about price and lower price
[42:47] alternatives before they purchase at the pharmacy counter. I appreciate President Trump's commitment
[42:54] to lowering drug prices, holding foreign countries accountable for benefiting from American medical
[43:02] innovation and protecting rural health care through price transparency and the $50 billion rural health
[43:10] transformation fund. The Trump administration's work to root out fraud, waste and abuse in health care
[43:18] programs is also ensuring resources are going to those who most need them, at the same time protecting taxpayers.
[43:27] Today's hearing is about the prescription drug supply chain as a whole. The entire prescription drug chain
[43:35] needs to be put under a magnifying glass. Accountability must follow the decision maker. No participant can hide
[43:44] behind the complexity of the system or conveniently shift responsibility. I appreciate Senator Durbin's partnership in
[43:53] holding this hearing. Today we'll hear testimony from a patient advocacy organization, from a co-founder of a
[44:02] Transparent Cost Plus Pharmacy, an Iowa Pharmacy, the Iowa Pharmacy Association, a healthcare economist, and a CEO of
[44:14] Illinois health clinics. They bring different perspectives. I thank each of these witnesses
[44:21] for being here today and I look forward to the discussion. Now to Senator Durbin.
[44:26] Senator Durbin Thanks, Chairman Grassley. If you attended the first half of this
[44:30] hearing this morning, there were some partisan moments. I'm sure you noted. I think you're going to find the
[44:36] opposite to be true when it comes to the second part of the hearing. Mr. Chairman, we're holding this important
[44:41] hearing to highlight the high cost of prescription drugs in America. It's no secret. People in the
[44:48] United States, families in the United States pay the highest prescription drug prices in the world,
[44:55] on average four times more than people in similar countries for similar drugs. Patients are forced to
[45:01] choose between drugs and food. Compounding this challenge is a lack of access to brick and mortar
[45:08] pharmacies. In the last 15 years, more than 800 community pharmacies in my state of Illinois have
[45:15] been forced to close their doors because of increased drug costs and declining reimbursement.
[45:21] Congress took a first step forward by addressing the high cost of drugs passing the Inflation Reduction
[45:27] Act in 2022. This law capped the price of insulin at 35 bucks a month. It set an annual out-of-pocket
[45:34] expense limit for seniors of $2,100 in 2016. It also let the executive branch negotiate with Big Pharma
[45:42] to lower prices under Medicare, something President Biden used to reduce drug prices by up to 79 percent.
[45:49] There's more work to do. Where should we start? Let me suggest direct-to-consumer drug ads. There are only two
[45:59] countries in the world that allow direct-to-consumer television ads for drugs. The United States is
[46:06] one of them. You know the other one? New Zealand. Big Pharma spends billions of dollars to flood the
[46:14] airwaves with advertisements. Why? To get American viewers of television to the point where they can not
[46:22] only pronounce Xarelto, but spell it. They've seen that ad so damn many times. And they also come to learn
[46:29] that these prescription drugs are miraculous in some respects. Pretty soon you're skiing or golfing
[46:38] or whitewater rafting. Only one other developed country allows this kind of thing, as I mentioned.
[46:45] In July, a citizen's petition was filed with the FDA asking them to ban these ads. The professional
[46:52] medical organizations want people to ban these ads because unnecessary and expensive drugs are being
[47:00] ordered by doctors and others when they're not necessary. If we cannot get rid of the ads,
[47:06] we should at least require Big Pharma to let people know how much these drugs cost. Is that an outrageous
[47:12] idea? How much does the RELTO cost? Chairman Grassley and I have a simple bill that we put in together
[47:19] that would require direct-to-consumer ads disclose the price charged by the drug company. It's a basic
[47:26] transparency issue to inform patients, and it's been supported by President Trump in the past.
[47:32] I hope we pass it before the end of the year. We must also address Big Pharma's anti-competitive
[47:37] schemes to maintain monopolies. The Senate Judiciary Committee is taking a leading role in stopping these
[47:43] abuses. In April 2025, this committee unanimously reported six bipartisan bills to address this issue.
[47:51] This includes my bill with Republican Senator Tillis to improve information sharing between the FDA and
[47:59] the Patent Office. Congress must pass these bills sooner rather than later. If this last election was
[48:06] about the cost of living, ask some people who are on prescription drugs the cost of their drugs
[48:12] and whether or not it creates a hardship on their family budget. This hearing is going to make clear our
[48:16] work to address high prescription drugs is far from over. Let's work together on a bipartisan basis to do
[48:22] something to help families afford a prescription drugs. Okay, I'll introduce four of the witnesses and
[48:33] Senator Durbin will introduce the other one. I'm going to start with Maris Basie, CEO Patients for
[48:42] Affordable Drugs Now. She co-founded the 100 campaign aimed at reframing the narrative around insulin
[48:54] access and reducing the barriers to access. Dr. Alex Omyanski is co-founder and CEO of the Mark Cuban
[49:07] Dr. Alex Omyanski is co-founder and CEO of the Iowa Pharmacy Association. Dr. Matthew Pitlick is the CEO of the Iowa
[49:27] Pharmacy Association, a person that I deal with quite often. Dr. Pitlick has led the Iowa Pharmacy Association
[49:38] since 2025. He has a doctor of pharmacy degree from Drake University and has worked in association with
[49:47] management, academia, industry, and health system practices. Fourth, Professor Nera J. Sudi is professor
[50:00] at the University of Southern California Price School of Public Law. He is also a senior scholar and
[50:08] founding member of the USC Schaefer Center for Health Policy and Economics. Now, Senator Durbin.
[50:17] Thanks, Mr. Chairman. Dr. Kareem Watson, welcome. Chief Executive Officer of the University of Illinois
[50:22] Health Mile Square Health Center and Assistant Vice Chancellor for Community-Based Practice
[50:28] at the University of Illinois in Chicago. A long distinguished career including leading a
[50:33] premier network of health centers advancing health equity across Chicago, Cicero, Illinois, and Rockford
[50:40] while helping strengthen and align community-based practices. Dr. Watson, thanks for being here today.
[50:46] Now, would you please stand because we swear people at these hearings. Do you swear or affirm that the
[50:56] testimony you're about to give before this committee will be the truth, the whole truth, and nothing but true
[51:01] the truth, so help you. It's all reaffirmed positively. So we'll go with Ms. Basie and then
[51:12] and with Ms. Dr. Watson. So would you please proceed, Merit. Chairman Grassley, Ranking Member Durbin,
[51:21] and members of the committee, thank you for inviting me to testify. I am here on behalf of the one in three
[51:28] Americans who are struggling to afford their prescription drugs and to urge Congress to pass
[51:34] bipartisan reforms that will increase competition and lower drug prices. My name is Merit Basie and
[51:41] I am the CEO of Patients for Affordable Drugs, the only national patient advocacy organization focused
[51:49] exclusively on policies that lower prescription drugs. We are bipartisan and do not accept funding from any
[51:57] organization that profits from the sale or development or distribution of prescription drugs. Founded nearly
[52:06] a decade ago by a cancer patient, David Mitchell, we have heard from tens of thousands of patients from
[52:13] across all 50 states and every single congressional district. Despite their different backgrounds and
[52:19] medical conditions, they are united by a common experience. They are struggling to afford the medicines they need.
[52:26] On behalf of those patients, I want to leave the committee with three points. First, patients are paying
[52:33] the price of a system that is rigged against them. Americans pay on average at least four times more
[52:41] than people in other high-income nations for the very same brand name prescription drugs. For families
[52:47] across the country, this is more than a financial burden. It's a health crisis that shapes every aspect of
[52:53] their lives. Patients are rationing medications, draining their life savings, and working multiple
[53:00] jobs just to afford their prescriptions. And even then, some are forced to go without the medications
[53:06] they need. And Americans understand that pharmaceutical companies bear the primary responsibility for those
[53:14] high prices. Second, drug companies exploit loopholes in our patent and regulatory systems to delay lower-cost
[53:22] competition and keep prices high. Our patent system was designed to reward genuine invention and encourage
[53:30] the development of life-saving novel treatments. But that bargain comes with a fundamental expectation.
[53:37] When legitimate monopoly protections end, competition should begin. But drug manufacturers manipulate the
[53:45] system to prevent the market from working as intended. They build walls of overlapping patents around existing
[53:52] medicines. They move patients onto slightly modified products as generics approach. They strike agreements
[53:59] that keep competitors off the market and exploit regulatory processes intended to protect patients. The result
[54:07] is the same. Less competition, longer monopolies, and higher prices. Take Kevin, a young man in Oregon living with
[54:15] Crohn's disease. He relies on Renvoke, a drug with a list price of more than $7,000. He told us,
[54:23] I have to choose between food and medicine. He struggles to access treatment consistently, and as a result,
[54:31] has never experienced full remission. Renvoke is protected by overlapping patents that delay competition from
[54:38] more affordable alternatives. For Kevin, the stakes are not abstract. Competition could bring down the price of the
[54:45] medicine he depends on. But until that competition arrives, he and millions of Americans will keep paying higher prices for
[54:52] longer. Third, Congress can restore balance to the system. The bipartisan bills that are the focus of today's hearing
[55:01] address systemic abuses by big drug companies and help restore balance, protecting genuine innovation while removing
[55:10] unnecessary barriers to competition. Competition is one of the most powerful tools to lower drug prices.
[55:16] When one generic enters the market, prices can fall by up to 39 percent. And when six or more competitors
[55:24] enter the market, prices can fall by up to 95 percent. These bills limit patent tickets, curb pay for delay deals,
[55:32] crack down on product topping, and deter the abuse of FDA citizen petitions. The choice is not between
[55:39] innovation and affordability. Patients need both. The founder of Patients for Affordable Drugs, David Mitchell,
[55:46] understood firsthand the importance of this balance. For 15 years, innovative medicines kept David alive
[55:53] with multiple myeloma and at more than $20,000 a year out of pocket. In January, those breakthrough
[56:01] options ran out, and David died. Congress has an opportunity and responsibilities to stand with the
[56:08] 9 in 10 Americans who want action to lower drug prices. Passing these common-sense bipartisan reforms
[56:15] before the end of the year would make the drug price system work better for the patients and taxpayers
[56:22] it was intended to serve, not those exploiting it. Thank you, and I look forward to your questions.
[56:28] Thank you. Now, Mr. Ashby.
[56:29] Alex is fine. I would first like to extend my thanks to the committee for inviting me here to speak
[56:39] today. At Cost Plus Drugs, we have spent years working diligently to find ways to reduce drug costs on
[56:45] every product we can. We now have over 3 million customers on costplusdrugs.com. Hundreds of hospitals and
[56:53] thousands of pharmacies buy from us wholesale, and we even manufacture products ranging from shortage cancer
[56:58] medicines to gene therapy. After all of that, we have found one fundamental driving force that pushes up
[57:05] drug costs in the United States dramatically over any other comparable nation. The power of the drug
[57:11] distribution and payment processing oligopolies in the United States. If you ask me what the top three
[57:18] things driving high drug costs for patients in America today are, I would say monopolies, monopolies,
[57:26] monopolies. Each of the big three pharmacy benefit managers, the PBMs, is meant to negotiate drug prices
[57:33] on behalf of their clients. And that should work in theory. They have enormous negotiating leverage,
[57:39] with two negotiating drug costs for over 100 million people through their rebate aggregators. That is more
[57:45] people than live in England, France, or Germany. And yet, branded drug costs in the United States are an
[57:52] average 3.2 times higher than in other comparable nations, even after rebates. How is that possible
[58:00] when we have so much more negotiating leverage? Either our negotiators are absolutely terrible at their
[58:07] jobs, or could they be pocketing the difference? There are two major ways that pharmacy benefit managers
[58:13] are able to raise prices. First, vertical integration. They set up their own pharmacies and even their own
[58:20] internal white label pharmaceutical companies. The big PBMs then get to pick which pharmacies to use
[58:26] and which products to buy, and effectively negotiate with themselves. Surprise, surprise, you don't get a
[58:32] great deal. It's like hiring somebody to negotiate the price of a used car for you, but that person also
[58:39] owns the car lot. It's not great. Second, they use a maze of elaborate financial engineering scams to upcharge
[58:46] on medications. There are dozens and dozens of these that each upcharge medication a little bit,
[58:52] but cumulatively a whole lot. Co-payment maximizers, accumulators, pharmacy switches, source programs,
[58:58] spread pricing, effective rate clawbacks, rebate guarantees, data fees, and inflation protection fees,
[59:05] etc., etc., etc. There are dozens of services on offer that each drive up the price of pharmaceuticals a
[59:11] little bit. But add them all together, and it's a whole lot. When I was coming out of my PhD, I was
[59:17] being recruited to be a quant, to quantitative analysis hedge funds. And you know, when you
[59:23] interview, you do technical interviews, prove you know how to do math, that kind of thing. And this was
[59:27] around 2007-2008. And I remember being shown these incredibly complicated financial instruments that no
[59:33] one had ever heard of at the time. Credit default swaps, collateralized debt obligations, and I'm kind of a
[59:39] blunt, awkward guy. I think I remember saying out loud, oh, so this is a scam. You take bad debt, added
[59:46] a layer of stochastic calculus on top of it, no regulator could hope to understand. And now, magically,
[59:51] it's good debt, which is much more expensive. The same fundamental scam is happening here.
[59:57] Dozens of layers of complicated math and legal machinations are obfuscating a very simple scam.
[1:00:03] They are hiding the true cost of drugs and marking them up a lot. And all of this is enabled by the fact
[1:00:09] that the big three PBMs control a virtual monopoly on drug contracting. The big three PBMs may control
[1:00:15] about 80% of the overall PBM market, but through their aggregators or GPOs, they control close to
[1:00:22] 100% of the commercial plan drug contracting market. That may sound odd. Can't anybody negotiate to buy
[1:00:30] drugs from a drug manufacturer? But the truth is no. The 50 or so smaller PBMs generally cannot contract
[1:00:37] with pharmaceutical companies directly. They can only contract by proxy through one of the big
[1:00:42] aggregators. At Cost Plus, we have found that the drugs we carry on average are about 50 to 60%
[1:00:48] less expensive than the final net price from PBMs. However, we have not been able to negotiate prices
[1:00:54] directly with patented brand and specialty drug manufacturers. We asked one manufacturer,
[1:00:59] why wouldn't you give us an offer? They responded, we're worried about retaliation. Another said,
[1:01:05] we have to be careful about working with Cost Plus due to the punitive nature of the big three.
[1:01:10] We have a lot of launches where the big three can hurt us. We asked another manufacturer, are you
[1:01:15] concerned about retaliation from the PBMs for working with us? They answered, yes, every drug company has
[1:01:21] a fragile product or two. Those are the pressure points. Cost Plus is a tiny company. The distribution
[1:01:28] side of our business only has 20 or so employees. Yet somehow academic studies and independent consultants
[1:01:34] find that we're able to get better prices than Fortune 20 companies representing hundreds of
[1:01:39] millions of people. We could do it again if we were allowed to contract with the brand pharmaceutical
[1:01:44] companies, but we are blocked. So that is my recommendation to the committee today. Take antitrust
[1:01:50] action against the big three PBMs. The Breakup Big Medicine Act and the Patients Before Monopoly Act
[1:01:56] are a great start. PBMs should not be allowed to negotiate drug prices with themselves, which is what
[1:02:01] is happening today. Thank you for your time and I look forward to questions. Thank you very much for
[1:02:07] your powerful statement. Mr. Pitlick, Dr. Pitlick. Chairman Grassley, Ranking Member Durbin and members
[1:02:14] of the committee, thank you for the opportunity to testify. I am a pharmacist. I grew up on an Iowa farm
[1:02:19] and became the first pharmacist in my family. Today I lead the Iowa Pharmacy Association representing
[1:02:23] pharmacists, pharmacy technicians, student pharmacists, and pharmacies across our state. I am here because
[1:02:28] patients deserve access to the pharmacy they trust. Employees deserve to know where their healthcare dollars go and
[1:02:33] pharmacies deserve a fair opportunity to compete. Many parts of the supply chain affect drug costs.
[1:02:38] Today I am focusing on PBMs. For years their practices have posed a serious challenge to community
[1:02:43] pharmacies and the patients they serve. Their decisions affect pharmacy choice, competition,
[1:02:47] and where prescription drug dollars go. Let me start with one Iowa family. A pharmacist shared with me the
[1:02:52] story of a patient whose medication was classified as a specialty medication. The local pharmacy was qualified
[1:02:58] to dispense it, but the health plan affiliated with the PBM required the patient to use the PBM-affiliated
[1:03:03] specialty pharmacy. That patient was the pharmacist's son. Some medications require specialized handling
[1:03:09] or clinical services, but when a pharmacy can meet those needs, patients should have a meaningful choice
[1:03:13] and that pharmacy should have a fair opportunity to compete. This is a question of competition across
[1:03:17] the supply chain. PBMs and health plans influence which pharmacies are in a network, what those pharmacies
[1:03:22] are paid, and where patients get their prescriptions. When a PBM or health plan is affiliated with a pharmacy
[1:03:27] competing for the same patients, we need to ask whether everyone is playing by the same rules. Pharmacies often
[1:03:33] need PBM contracts to serve patients who use insurance, yet smaller pharmacies have little
[1:03:37] ability to negotiate and payment terms are not always clear. These pharmacies are expected to care
[1:03:42] for patients and keep their doors open under contracts that can leave them losing money on the very
[1:03:46] prescriptions that they dispense. It is difficult to invest, compete, and serve a community when you
[1:03:50] cannot predict whether you will be paid enough to cover your costs. Transparency matters just as much.
[1:03:55] Employers and health plans need to see what they pay for, what the pharmacy receives, and how rebates and fees
[1:04:01] affect the final cost. Without that information, they cannot compare options or hold their partners
[1:04:05] accountable. For nearly two decades, Iowa has worked on PBM reform. Our 2025 law addressed reimbursement,
[1:04:12] pricing, and pharmacy choice. It was challenged, and the Eighth Circuit heard arguments in September,
[1:04:17] and we are awaiting a decision right now. States need room to lead, but a national marketplace also
[1:04:22] calls for federal action. I encourage Congress to address unfair PBM practices and conflicts of interest,
[1:04:27] require transparency and audit rights, protect patient choice, and make pharmacy reimbursement and
[1:04:32] audits fair and predictable. Two bills that will help are Senate File 526, the Pharmacy Benefit Manager
[1:04:37] Transparency Act, and Senate File 4509, the Patients Before Monopolies Act. I also urge the FTC to complete
[1:04:44] its PBM study and release its findings and recommendations. For too long, powerful entities have used their position in
[1:04:50] ways that disadvantage patients, local pharmacies, and employers. In Iowa, we believe that everyone deserves a fair shot.
[1:04:56] Businesses should succeed by delivering better value and service, and pharmacies should have the
[1:05:00] opportunity to compete based on the care they provide. Iowa's pharmacists are not asking for
[1:05:05] protection from competition. We are asking for competition. This committee named the hearing well.
[1:05:10] Sunshine matters because markets cannot discipline prices they cannot see. Patients deserve affordable
[1:05:15] medications, and employers deserve to know where their dollars are going. Pay transparency with
[1:05:19] enforceable rules of fair competition, and the market can reward lower costs, better service,
[1:05:24] and better care. Thank you, and I welcome your questions. Thank you, Dr. Baitlake. Now,
[1:05:28] Professor Sudet. Chairman Grassley, Ranking Member Durbin, and members of the committee,
[1:05:40] thank you for inviting me back. Last time I testified before this committee, I was asked for two things
[1:05:47] I would do to fix PBMs. I said transparency and fiduciary responsibility for PBMs. I also recommended
[1:05:55] basing patient out-of-pocket cost on the net price of the drug after rebates. And when asked whom should
[1:06:03] PBMs serve, the plan or its members, I said the members. Since then, there has been real progress on
[1:06:12] transparency. The Department of Labor now requires PBMs to disclose to employers how they are paid with
[1:06:20] annual audit rights. The Consolidated Appropriations Act added similar reporting, and in addition,
[1:06:28] it requires PBMs to pass through all manufacturer rebates to employer plants. In Medicare Part D,
[1:06:35] it goes further and limits PBMs to flat service fees. These reforms help align PBMs with the health
[1:06:45] plans they serve. But aligning PBMs with plan does not mean aligning PBMs with patients. Consider two
[1:06:55] drugs that work equally well. Drug A has a list price of $1,000 and a rebate of $650. So the net price of
[1:07:06] the drug is $350. Drug, the patient pays about 20% of the list price, which is $1,000 or $200 is
[1:07:17] what the patient is paying, and the plan is paying the remaining $150 for this drug. There's a cheaper
[1:07:23] drug, Drug B. It has a list price of $400 and a smaller rebate of $100. So the net price of the drug
[1:07:31] is $300. The patient now pays $80 and the plan pays $220. So plans prefer Drug A, the one with high list
[1:07:43] price and high rebates, while patients and the healthcare system prefers Drug B with a lower net
[1:07:50] price and lower out-of-pocket cost for the patient. But a PBM working in the best interest of a plan
[1:07:58] would choose Drug A and increase costs for patients. This is because cost sharing is based on the list
[1:08:05] price of the drug rather than the net price after rebates. So how do we make sure that PBMs work for
[1:08:12] lowering costs for patients and the healthcare system? I recommend three steps. First, make PBMs
[1:08:19] fiduciaries. The Bipartisan Fair Act, co-sponsored by Chairman Grassley, does this. PBMs say they negotiate
[1:08:27] hard and manage benefits efficiently. Those are discretionary decisions, and they should come
[1:08:34] with accountability to patients and plan members. Second, base patient cost sharing on the prices after
[1:08:42] rebates. This would not only lower out-of-pocket costs for patients at the pharmacy counter,
[1:08:47] it would also align the incentives of plans and PBMs with patients and plan members. Now both the
[1:08:55] patient and the plan save money when they choose drugs with lower net prices. Third, the FTC Settlements
[1:09:04] and Express Scripts new model offers this design, which shows that this design is possible,
[1:09:10] but offering a better design is not the same as patients getting it. Plans and employers can opt
[1:09:17] out, and as I explained earlier, many have a financial reason to do so. This protection should
[1:09:23] be a requirement, not an option. There are trade-offs here. With cost sharing based on list prices,
[1:09:30] today the sickest patients pay more so that everyone else pays slightly lower premiums.
[1:09:36] If cost sharing is based on net prices, the sickest patients will pay less, but premiums will increase.
[1:09:43] In Medicare, this might increase government spending as the government subsidizes premiums,
[1:09:49] so Congress could start with employer plans first. Finally, we should use the new information
[1:09:57] from the Department of Labor regulations and the CAA to promote competition. The FTC
[1:10:05] should report each year on the state of PBM competition, and the Department of Labor should
[1:10:11] require a standard format so that employers can compare offers from competing PBMs. Antitrust
[1:10:18] enforcers should use the data to determine whether integrated pharmacies still steer patients to their
[1:10:24] own pharmacies, and if steering continues, Congress should consider separating PBMs from pharmacies.
[1:10:31] Congress has helped employers see how PBMs are paid. Now we must make PBMs accountable and ensure that
[1:10:39] discounts reach patients at the pharmacy counter. Thank you, and I look forward to your questions.
[1:10:45] Thank you, Dr. Sidon. Now, Dr. Watson.
[1:10:49] Dr. Watson. Good morning, Chairman Grassley and Ranking Member Durbin and members of the committee.
[1:10:54] Thank you for holding this important hearing. I have devoted my career to public service as a cancer
[1:11:00] researcher and administrator in both Chicago and at the National Institute of Health.
[1:11:05] Mile Square Health Center, one of the oldest community health centers that I have the privilege
[1:11:08] of serving as the CEO, is part of the University of Illinois at Chicago, and we operate 12 community
[1:11:14] health centers in Chicago, Rockford, and Cicero, Illinois. We provide comprehensive primary care for
[1:11:20] some of the most underserved communities in the state. Many of our patients live at or below the federal
[1:11:25] poverty level, have public insurance, or are uninsured. So the topic of prescription drug
[1:11:30] costs matters a great deal to us. Some of our patients, they have to choose between paying for
[1:11:35] food or the medications that they need to stay healthy. On top of that, they have to deal with
[1:11:40] the burdensome prior authorization requirements that change from year to year and uncertainty about
[1:11:46] where the drugs are covered by their insurance and what their co-pays will be. A number of our patients
[1:11:50] are older and live in rural communities, and they struggle to understand these complicated and
[1:11:55] changing insurances and PBM requirements. Affordability and health literacy are not the only challenges
[1:12:02] facing our patients. They also have to deal with the difficulties accessing pharmacy services.
[1:12:07] Community pharmacies are facing significant financial pressures caused by declining prescription
[1:12:13] reimbursement and rising medical acquisition costs, among other issues. As Senator Durbin noted,
[1:12:18] between 2009 and 2021, 838 community pharmacies closed in Illinois. More than 73 percent of Illinois
[1:12:27] counties are categorized as pharmacy deserts, with low-income urban and rural communities at particularly
[1:12:33] high risk. Those communities often lack access to reliable, affordable transportation as well.
[1:12:40] Several of our clinics have been impacted by pharmacy closures. When a neighborhood pharmacy closes,
[1:12:45] a short walk can turn into a 30-minute bus ride each way, which is a real hurdle for patients who are elderly,
[1:12:52] sick, caring for children, or can't take time off work. In rural parts of our state, the nearest pharmacy
[1:12:58] may be many miles away with no public transportation at all. Even when they can find a way to get there,
[1:13:04] patients also need to determine if the new pharmacy is in the PBM's network or if their out-of-pocket costs
[1:13:09] will increase. At Mile Square, we spend a lot of time and resources trying to ensure that our patients can get the
[1:13:16] medication they need. I'd like to give you one recent example from a patient who agreed to share his experience.
[1:13:22] After losing his job, he found himself uninsured and unable to qualify for Medicaid. We made sure that he continued to
[1:13:29] receive both his medical care and his medications that otherwise would have been difficult for him to afford.
[1:13:34] For example, he needed a maintenance inhaler that would have cost more than $100. We were able to provide
[1:13:41] him that inhaler at a cost of just $5. He estimated that several of his medications together could cost
[1:13:47] more than $200 per month, even using discounts. Instead, he ended up paying $40 total through Mile Square.
[1:13:54] Ensuring access to care and medications is part of our mission, but that mission does not come cheap.
[1:14:00] Our own on-site pharmacy in Chicago is facing some of the same pressures as community pharmacies are
[1:14:06] facing around the state and in rural communities, particularly reimbursement rates that have not
[1:14:10] kept up with the cost of acquiring and dispensing drugs. The drugs we prescribe most tend to be
[1:14:16] generics or other medications with particularly low reimbursement rates. Our pharmacy costs have
[1:14:21] increased from 6.6 percent of our total operating expenses about 8 to 10 years ago to in 2027,
[1:14:28] our fiscal year budget includes 12 percent of pharmacy costs to support our operating budget.
[1:14:33] The pharmacy has lost close to $3 million over the last three years. So as Congress looks for ways to
[1:14:39] make drugs more accessible and affordable, I hope you will consider legislation to ensure fair
[1:14:44] reimbursement practices that account for both drug costs and clinical services by community pharmacies.
[1:14:51] Thank you for the opportunity to testify today and I look forward to answering your questions.
[1:14:55] We'll have five minute round for questioning. I'm going to start with my fellow Iowan.
[1:15:00] It's been four years since the FTC began their study of PBMs. Patients, rural pharmacies in Congress
[1:15:10] are still waiting for the study and its recommendations. So please tell me, Dr. Pitlick, how is the delay of the FTC's final
[1:15:19] report on PBMs impacting patients and rural pharmacies and why is getting this report so important?
[1:15:28] Thank you, Senator. Thank you for the question, Mr. Chairman. The two patients, the FTC report is
[1:15:33] important. It's just right now status quo essentially, right? The interim reports are
[1:15:37] non-binding, but they gave great information. They gave great insight. But like you said in your opening statement,
[1:15:42] we are awaiting the full report with legislative action that Congress can take. And I think that
[1:15:47] Congress is deserving of that, the public is deserving of that, and taxpayers deserve it as well.
[1:15:51] Mr. Casey, last year this committee took a comprehensive report for reducing drug costs.
[1:16:00] I've talked about the bills that got out of committee. I won't repeat that for your question.
[1:16:05] These bills will bring cheaper treatment faster to the market and hold drug companies and PBMs accountable.
[1:16:13] The Senate has now passed just one of these six competition bills. So for you, what impact would
[1:16:20] these remaining five bills have on patients and why should the Senate act now?
[1:16:27] Thank you for your question. Lower cost competition is essential for the one in three Americans who are
[1:16:34] struggling to afford their prescription drug prices. These bills, if passed together, would help close some of
[1:16:41] the loopholes in the patent and regulatory systems that the pharmaceutical industry uses to abuse
[1:16:50] the system and keep prices high at the expense of American patients and maintaining their monopolies.
[1:16:56] We need lower cost drugs sooner so that patients can benefit and so that taxpayers can benefit too.
[1:17:03] These bills would all save money and they would make a difference for millions of patients around the country.
[1:17:10] Mr. Dr. Omerski, according to a recent study, Part D, Medicare could save as much as $8.6 billion annually if it were
[1:17:24] using the same pricing for certain generic drugs as the cost plus drug companies use. In other words,
[1:17:33] you're getting a better deal for patients while under the Part D program, PBMs drive up the cost for seniors and
[1:17:41] taxpayers. So to you, how does the cost plus drug company achieve these lower prices and what barriers
[1:17:49] does a company face when entering or expanding in the prescription drug market?
[1:17:56] Yeah, it's very simple. We try to go back to the 1850s in terms of our pricing model. You can go to our
[1:18:04] website and you can see what it is exactly we pay for the drugs. So you can see the real cost of the drugs
[1:18:09] from the manufacturer on our website for each individual drug. We add a 15% margin as our markup,
[1:18:16] $5 fee to pay our pharmacist, $5 shipping and handling, and that's the total cost of the medication.
[1:18:23] Everything else, that entire $8.6 billion difference, that's just intermediaries in the supply chain
[1:18:30] adding their markup. And on certain drugs, specialty generic drugs, we can be 95, 99% less expensive
[1:18:38] than your out-of-pocket deductible costs. That sounds crazy, but that's just the extent of the scam.
[1:18:45] You might get asked to pay a $3,000 copayment for imatinib, for chronic myelogenous leukemia.
[1:18:52] From us, exact same drug, exact same drug company, about $30 for the same medication. So yeah, it really is just
[1:19:01] these predatory intermediaries driving up costs, particularly specialty generics, biosimilars.
[1:19:07] And the one thing we cannot do at the moment is get access to the branded, patented, and specialty
[1:19:13] drug products. If we could break through that, I think we could drive down drug costs for the country
[1:19:17] much, much further. Okay, this will be my last question. Professor Souda, I'm glad the Department of
[1:19:24] Labor recently implemented PBM reform for some employer-sponsored health plans. Under federal
[1:19:31] rules for employer-sponsored health plans, there's a question as to whether PBMs have a
[1:19:37] fiduciary responsibility to health plan sponsors. PBMs would argue that they're getting the best deal for
[1:19:44] their clients. PBMs opaqueness and tactics make me question that position. I'm all in for regulating PBMs,
[1:19:55] but we ultimately need a comprehensive mechanism to hold these PBMs accountable. Otherwise, we're playing
[1:20:02] whack-a-mole with PBM behavior. You talked about this in your 2025 testimony before this committee.
[1:20:10] So why would establishing an explicit fiduciary duty standard, given the recent Department of Labor
[1:20:18] recommendation, help ensure PBMs have a duty to work for the benefit of the consumer?
[1:20:24] Thank you for the question, Chairman Grassley. So what the new laws do, the Department of Labor
[1:20:32] regulations and CAA is they let employers or they ask PBMs to disclose to employers how they're making
[1:20:42] money and their contracts with pharmacies. But disclosure is not enough to change their practices.
[1:20:49] As Dr. Alex said, you know, there's only three PBMs and if every PBM is doing the same games,
[1:20:56] switching PBMs is not going to help. So what you need is accountability ultimately to plan members
[1:21:04] and as the FAIR Act does, it gives fiduciary responsibility to PBMs. And that fiduciary
[1:21:12] responsibility is owed to employees and plan members. So even if employers don't act under ERISA,
[1:21:20] the Department of Labor or employees could act and hold PBMs accountable. And ultimately, if PBMs say
[1:21:28] they're doing a great job for patients, be accountable for it. And that's what fiduciary
[1:21:34] responsibility does. Thank you. Thank you. So I'm trying to get an understanding of socialism.
[1:21:46] We're talking about Medicare and Medicaid and the cost of prescription drugs. So let me just ask some
[1:21:54] hypothetical questions. Is it true or not true that 95 percent of the new drugs that are available in
[1:22:01] America started with federal research at the National Institutes of Health? So the starting point is the
[1:22:11] American people are already paying for the basic research that leads to the drugs which they need
[1:22:17] to stay healthy. True? Let's talk about Eliquis for a moment. And let's talk about a call that many
[1:22:28] politicians are making for Medicare for all. Let's take a look at Eliquis under Medicare. Let me see if
[1:22:36] what I have here is correct. Medicare, pardon me, Eliquis fell into these Part D drugs, 10, that were
[1:22:45] reduced in cost for Medicare. Eliquis originally was $521 for a 30-day supply. It's now $231 for a 30-day
[1:23:01] supply. A pretty dramatic cost because the government said to the maker of Eliquis, whoever it is,
[1:23:08] you're entitled to a profit, but you're charging too much and we won't pay it under Medicare.
[1:23:12] Period. Out of the 70 million people who are under Medicare, which some politicians brand to socialism,
[1:23:21] but under Medicare, of the people under Medicare in the United States, 70 million of them,
[1:23:29] 4 million take Eliquis. So what has happened to the cost to the federal government of this Part D
[1:23:36] mandate by the government to reduce the 30-day cost of Eliquis from $521 to $231?
[1:23:43] The federal taxpayers have saved $10 billion, $10 billion for this blood thinner. That's pretty
[1:23:53] amazing. So the question in my mind is, well, why don't we just go ahead and go all the way?
[1:23:59] Why don't we put everybody under Medicare? Let's cut the crap. I mean, the doctors, patients alike can
[1:24:06] hardly understand the system that we're describing today. The cost is impossible for them to manage
[1:24:12] unless they happen to be under a socialist program in some people's estimation of Medicare. Mr. Oshmansky,
[1:24:20] I listened to you explain how you're Mr. Cuban, who I haven't met a couple of times, has been able to
[1:24:28] give people discounts on drugs just by paying what the drug companies are charging. But the federal
[1:24:33] government is paying more. Why? What's going on here?
[1:24:37] Yeah. Again, it's the markups from the intermediaries in the supply chain. And as the chairman
[1:24:46] was saying, I think what you're describing is actually very bipartisan. You know, credit where
[1:24:51] credit is due for the TrumpRx program, kind of the same thing. You cut out the middlemen. You let
[1:24:57] the government negotiate prices directly. The drug prices go down, be that under a Medicare for All
[1:25:03] framework, be that under. So why do Americans pay four times as much for these drugs as other countries?
[1:25:08] Why? Yeah, they're getting ripped off. That's all there is to it. There's three companies that
[1:25:13] effectively, you know, there's a complicated financial maneuvers how this happens. But
[1:25:17] effectively, they buy all the drugs, they mark them up a lot, and they resell them. And we've just
[1:25:23] kind of allowed it to happen because we're used to it. Anybody here opposed to Medicare for All? Speak up if
[1:25:31] you are. I think I would have to think about it, and I wouldn't say I'm in agreement
[1:25:37] with Medicare for All. Okay. I'll put you down as undecided. There will come a time when you have
[1:25:43] to vote, but not now. Anybody else have any thoughts? Ms. Basie? I think to achieve Medicare
[1:25:49] for All, we need to tackle the less price of drugs. One of the primary challenges to achieving that
[1:25:56] would be ensuring that the drugs that are covered and paid for are not being charged to Americans at
[1:26:04] four to eight times the price of... Well, Medicare does that with the Part D, right?
[1:26:09] With Part D currently, correct. Yeah. So we can do it. They say to the direct companies,
[1:26:14] you make a profit, but not the profit you want to make. Yeah. The U.S. is the only country,
[1:26:20] high-income country in the world that doesn't negotiate for all drugs. I want to tell you,
[1:26:24] you're going to get lost in the sauce if you try to understand PBMs and how they work. If you read
[1:26:29] a PBM defense of what they're doing, it sounds perfectly reasonable. We're bringing competition
[1:26:34] and rebates and cuts and discount. And yet when it's all over, Americans pay four times as much
[1:26:40] as other people around the world for the same drugs. So the system with the PBMs is hardly working
[1:26:46] to the benefit of the consumers, the best that I can see. Let me also ask Dr. Watson, I've been to
[1:26:56] Mile Square. And the people who come in there, some of them are covered by Medicaid, correct?
[1:27:01] Correct. Yes, sir. And now there's a talk about taking a trillion dollars out of Medicaid. What is
[1:27:06] that going to do? Thank you so much for that question. The Medicaid cuts would have a drastic
[1:27:11] impact on our patient population. This was part of the big, beautiful budget bill, Medicaid cuts.
[1:27:17] Over 60 percent of our adult patients are covered by Medicaid. And also that means that we are,
[1:27:22] we're the safety... Mile Square is a fairly qualified health center that serves as a support for
[1:27:26] keeping our patients out of the emergency room, ensuring that they get the timely care that they
[1:27:31] need. So if the people are not covered by Medicaid, what are they covered by? They're uninsured. And
[1:27:36] if they're uninsured, the cost we, as a fairly qualified health center, sir, we still will serve
[1:27:40] those patients, but our uncompensated care will go up. And that means that those patients will be,
[1:27:46] they will end up in our emergency rooms, they will end up sicker, and the cost of health care will go
[1:27:50] up because they lost their coverage. Tony Preckwinkle, the president of the Cook County Board, came to see me
[1:27:56] to talk about Stroger Hospital, the big public hospital. Their charity care has gone up in
[1:28:02] costs because people are not covered by insurance, can't afford insurance anymore, from 19 percent of
[1:28:07] their workload to 25 percent. She said, we can't manage this. Are you going to face the same thing?
[1:28:13] We are already facing the same thing, sir. Our uncompensated care, our uninsured rate
[1:28:18] almost doubled, went up from about 6.5 percent last year. How can this be good for the country,
[1:28:22] for more and more people to be uninsured? Have you ever been uninsured with a sick baby? Yes.
[1:28:28] You'll never forget it as long as you live. And we're going to do this to millions of people now?
[1:28:34] I've lived that life, Senator. Prior to being the CEO of Mile Square, I actually got my care there,
[1:28:39] and I was uninsured. And to think about what that meant through, you know, it was a cost of care,
[1:28:44] and a lot of burden went into that. So when I think about what that's going to do to our patients,
[1:28:49] we're going to have a sicker patient population, and it's going to lead to rising health care costs.
[1:28:53] What do you think of Medicare for all? I think there could be one possible solution.
[1:28:57] Thank you, Mr. Chairman. Senator Lee. Thank you, Mr. Chairman, for holding this
[1:29:02] hearing. Thanks to each of you for being here. Ms. Basie, I'd like to start with you. For the
[1:29:07] last few years, I've been working hard to try to eliminate unnecessary switching studies
[1:29:12] when it comes to interchangeable biosimilars. As you point out, competition really is the best
[1:29:21] answer to pricing issues that we face when it comes to prescription drugs. Now, your testimony
[1:29:27] endorses my bill as 1954, the Biosimilar Red Tape Elimination Act. And it describes the patients that,
[1:29:37] the savings that patients receive, would receive, when generics and biosimilars are allowed to compete.
[1:29:46] Sometimes that happens, sometimes it doesn't, because red tape gets in the way. Now, in addition to the
[1:29:52] duplicative regulatory requirements, what should Congress remove to get affordable biosimilars in
[1:29:59] place, and to get those and the cost savings they bring to patients sooner? Ms. Well, we, as you know,
[1:30:06] support your Biosimilar Red Tape Act, and I appreciate that, because it's, it will be critical
[1:30:13] to ensuring that we can advance, we can speed those generics and biosimilars to market. The
[1:30:19] interchangeability is key, because it will also save taxpayers a lot of money as well. And one of the,
[1:30:27] as we've already highlighted, one of the most important ways to bring down the cost of medicine
[1:30:33] is through competition. And right now, we know there's also, I think, about 118 Biosimilars that
[1:30:41] are coming near to the end of their patent term, but only a fraction of those, about 12,
[1:30:48] have biosimilars in, in, in the pipeline. So we need to encourage more. Okay, so the, the,
[1:30:58] one of the things preventing that is this duplicative unnecessary switching study requirement,
[1:31:07] right? We eliminate that requirement, I would assume that helps close that gap. In other words,
[1:31:14] when you've get, when you've got biologics on the market today, nearing the end of their patent
[1:31:22] exclusivity, you'd see a lot more people, a lot more companies preparing to launch a biosimilar,
[1:31:31] would you not? That would be the goal, but also that's, that's one of the advantages of this bill.
[1:31:39] It would, it would, but at the same time, we need to close a lot of the loopholes in the current patent
[1:31:46] system to ensure that pharmaceutical corporations are really driving towards the novel innovations that
[1:31:54] patients need, right? So not just these, uh, uh, patents that are duplicative that prevent, uh,
[1:32:02] new drugs coming to market, but instead allow those corporations to extend the monopolies as long as
[1:32:08] possible. And who ends up paying the price? It's, it's, it's patients. Like we know this from these
[1:32:13] examples of drugs like Keytruda, that's one of the best selling drugs in the world. Uh, I think it cost
[1:32:19] about, uh, US taxpayers, patients an additional 16 billion dollars last year because of these patent
[1:32:26] thickets. Uh, and it's completely unnecessary. They have had decades of, uh, monopoly time to be able
[1:32:33] to charge as much as they want. Uh, but now it's time for, uh, generics biosimilars in this case to be
[1:32:41] able to come to market so that cancer patients, uh, are not paying the $6,100 a vial that we know
[1:32:47] patients in our community are being forced to pay and possibly on these fixed incomes. Uh,
[1:32:54] and 50% of Americans right now are actually draining their savings, uh, and going bankrupt
[1:33:01] because of the high price specifically of these cancer drugs. And it really doesn't need to be this
[1:33:06] way. And nothing can bring these prices down quite like competition. Now in your testimony, you cite
[1:33:12] evidence indicating that having even just one generic competitor can reduce a drug's cost by, I believe,
[1:33:20] 39%. Correct. And that when you add more competitors to it, uh, the benefits, uh, reaps become even more,
[1:33:28] uh, stunning that six or more, uh, competitors can reduce it by as much as 95%. So what, what is it that's
[1:33:37] preventing those competitive cost savings from reaching patients promptly after a generic or a,
[1:33:43] uh, biosimilar, uh, has a pathway to approval? Well, right now there's a lot of different tactics
[1:33:50] that the industry is using to ensure that, uh, they are maintaining their monopolies. Like patent
[1:33:57] thickets. Like patent thickets, pay for delay deals, citizen petition, uh, sham citizen petitions,
[1:34:02] all of the bills that, uh, we, uh, discussing essentially today, they all, uh, tackle a different
[1:34:09] piece of the system. And because there's so many different tactics that they use, we need to make
[1:34:14] sure that all these loopholes are closed. So the innovation that patients really need, uh, is,
[1:34:20] is the primary focus and not the extension of these monopoly periods just so that they can take
[1:34:25] advantage of American patients. Mr. Chairman, I've got one brief follow-up if I may finish that one.
[1:34:30] So if Congress could remove one barrier, just one barrier, uh, to this, um, what, what measure
[1:34:37] would most credibly show that patients, uh, not just manufacturers or intermediaries would be
[1:34:42] benefiting? I, I, I don't think we can just remove one measure. We need to remove all of them. This is
[1:34:48] why all of these bills must be passed together because not only do they save taxpayers money, but they
[1:34:54] will reduce costs, uh, for patients and it will speed those generics to market and biosimilars.
[1:35:00] There's so many different ways that, uh, expensive lawyers have been paid to manipulate the system.
[1:35:06] And I imagine it will continue to be that way. We need to catch up, uh, and we need to make sure
[1:35:12] that America is able to be focusing on genuine innovation, not gamesmanship. It doesn't make
[1:35:17] America more, uh, competitive in the end. And this is really about competition for American patients.
[1:35:24] And so that we can get the new drugs that would have saved, for example,
[1:35:27] the life potentially of the founder of P4AD who, uh, was waiting for that drug at the end and it never
[1:35:33] came. Thank you very much. Senator Bloom was on then Senator Kennedy.
[1:35:39] Thanks, Mr. Chairman. Thank you all for being here today. Um, as you all know,
[1:35:45] and the American public does not know, pharmacy benefit managers have become immensely powerful
[1:35:55] intermediaries that can influence the cost of prescription drugs, perhaps more than any other
[1:36:02] single institution. Many are vertically integrated with their own insurers, their own medical providers,
[1:36:11] their own private drug labelers and pharmacies. And today the three largest of those PBMs control
[1:36:17] approximately 80% of the market and the six largest PBMs control 96%. As a result of the vertical
[1:36:26] integration, there have been significant concerns that PBMs engage in patient steering, that is directing
[1:36:36] patients to go to their own pharmacies rather than potentially the pharmacy of choice. Senator Lee just
[1:36:45] talked about competition. Clearly the current structure of the PBMs inhibits competition. Uh,
[1:36:54] Mr. Pitlick, perhaps you can talk about the potential impacts of patients steering on independent
[1:37:02] pharmacies and their ability to compete. Absolutely. Thank you for the question, Senator. In my testimony,
[1:37:07] I gave an example of that patient steering of, uh, a PBM affiliated, steering of a, of a specialty
[1:37:13] medication to a PBM affiliated pharmacy from a, from a pharmacist. The patient was his son. And so
[1:37:19] it just impacts things. It fragments care at best. I think, um, that patient may or may not know what
[1:37:25] the medication is, get educated, know how to use it. They're often complex medications. At worst,
[1:37:31] that patient, that medication shows up on the patient's doorstep, doesn't know how to use it,
[1:37:34] doesn't take it, the condition gets worse and or they take the medication, they don't know how to use it,
[1:37:38] and they have an adverse reaction of nobody to go to, to talk to because there's often nobody to talk to
[1:37:43] when these specialty pharmacies, uh, ship their medications to their door. So the impact is not
[1:37:47] only on pocketbooks, it's also potentially on health because they may not be warned or protected
[1:37:54] against side effects that would happen, that would be forestalled if they went to their pharmacies of
[1:38:01] choice. Yes, sir. That's correct. Uh, let me ask you and Mr. Sood, um, because he discusses imposing a
[1:38:10] fiduciary duty on PBMs which would force them to act in the best interest of patients rather than their
[1:38:20] own profitability. Uh, how would imposing a fiduciary duty on PBMs protect against potential conflicts such
[1:38:30] as patient steering and health patients? So, uh, what a fiduciary duty, uh, does is it makes the PBM, uh,
[1:38:40] accountable, uh, to patients and plan members? Uh, so if PBMs, uh, do activities that profit them at the
[1:38:49] expense of patients and plan members, uh, the employers or plans can take PBMs to code. If employers
[1:38:57] or plans don't act, then plan members themselves can act. And, uh, under ERISA, I believe, uh, the Department of
[1:39:05] Labor can also act. Would there be an intent requirement in that standard? Uh, that I'm not sure about.
[1:39:16] Let me ask you, uh, Ms. Basie, um, as, as you know, um, this Congress, the Inflation Reduction Act,
[1:39:38] penalizes pharmaceutical companies for raising the cost of drug prices faster than the rate of inflation.
[1:39:45] They have to pay Medicare a rebate. Would expanding the regime or the cap on prices or an inflation
[1:39:55] rebate, similar to the one in the Inflation Reduction Act to all drugs, not just those that are covered
[1:40:02] now, have an effect on patient access to pharmaceuticals? Yeah, we, so we would support
[1:40:09] copay caps, but at the end of the day, we all, we need to tackle the list price, uh, of, of drugs. And it
[1:40:16] is principally the pharmaceutical industry that has that power. They set those prices and they increase
[1:40:22] those prices multiple times a year. And the U.S. is the only high-income country that doesn't engage
[1:40:29] in that mechanism from day one, right? And so copay caps will really help patients. But if the list
[1:40:37] price of drugs just continues to rise, uh, there is questions about how we would be able to afford that.
[1:40:44] So we would need to balance that by ensuring that we can negotiate more drugs, uh, and bring the, down
[1:40:50] those prices to ensure that Americans could pay, uh, have a better deal. Thank you. My time is expired. Thank
[1:40:56] you. Now we go to Senator Kennedy, then Senator Booker. I object. Okay. Senator Kennedy. We, uh, we need these
[1:41:12] pharmaceutical drugs. The world needs them. Um, they help us live longer and they improve the quality of our life.
[1:41:24] It's expensive and very risky to develop these drugs. Only the private sector can do it. If you
[1:41:39] sign this job to government, it'll never happen. Those who risk their capital to develop these drugs
[1:41:49] are entitled to recoup their costs and a fair return on their investment. Otherwise, they're not going to
[1:42:01] develop the drugs. We ought to be looking for ways to incent them, or at least not to discourage them. But
[1:42:15] after that, it's the consumers that should be able to benefit from these drugs. And, and the testimony
[1:42:29] I'm hearing, all of us knew it coming in here. I don't know how many of these hearings I've been to
[1:42:35] a squillion where we ask questions and talk about it. Nothing happened. The problem with our market
[1:42:47] is the intermediaries. That's clear. It's the intermediary. And that's what this legislation will,
[1:42:57] in part, in part, address. Now, I know my colleagues on the Democratic side are excited about Medicare for
[1:43:09] all. Um, the problem with Medicare for all is that it's not going to be Medicare. It's going to be a different
[1:43:20] animal. The other problem is that 50% of Americans, uh, and about 200 million Americans get, aren't, aren't on
[1:43:32] Medicare. They're on their private insurance to their employer. And they're pretty happy with it. And if you tell them,
[1:43:38] they got to give it up, they, they've seen that vampire movie before. Trust us. If you like your
[1:43:45] insurance, you can keep your insurance. That's not what's going to happen with Medicare for all. But I
[1:43:50] know my colleagues on the Democratic side are hell bent for leather to try. I would encourage them
[1:43:58] before they do that, to try to deal with this issue. I am embarrassed that my side has been in
[1:44:11] control for two years and we've done nothing. Zero. Zilch. Nada. We haven't even tried to move this
[1:44:24] legislation. We tried to make football coaches happy. So, and we're, we're not going to have another
[1:44:35] chance. We took our shot and we missed. I hope my Democratic colleagues will, will start in bite-sized
[1:44:45] pieces with legislation like this. If I could change one rule in the United States Senate,
[1:44:53] it would be that one person should not have the power to decide what the United States Senate can
[1:45:00] consider on the floor of the United States Senate. It's not right. And it keeps us from doing this
[1:45:09] kind of legislation. Who disagrees with anything I've said? You don't have to opine on the United States
[1:45:19] Senate. That's our problem. We've screwed it up and only, only we can fix it. But it is unconscionable
[1:45:29] to me that we haven't even been given an opportunity to vote on this legislation. Who thinks I'm wrong?
[1:45:43] I would, if, if I may. Sure. Challenge the, the note about the government funding drugs because
[1:45:56] ultimately it is the NIH that funds the large majority of, uh, drugs, uh, from basic research
[1:46:04] all the way through to clinical trials, much more than any single pharmacy. The problem with that,
[1:46:07] Madam CEO, is they're good, they've got big brains and they're good at developing the concept. But you
[1:46:14] ask them to bring it, bring that product to market, they'll screw it up six days to Sunday. You got to
[1:46:20] have business people do that. That's why we need to close the loopholes in, in the system that allows these
[1:46:26] pharmaceutical corporations essentially to be lazy by increasing, uh, extending their monopolies
[1:46:33] and just benefiting at the expense of American patients. I don't think we're disagreeing. I said
[1:46:37] that. But, but, um, you're acting as if pharmaceutical drug companies are Darth Vader. They're the ones who
[1:46:45] develop these drugs. The problem is, as I see it, and they're entitled to a fair return. The problem is,
[1:46:53] I see it in the mid years. Senator Booker. The parasites. Ninety-nine percent of the, of the drugs
[1:47:01] that were approved by the FDA, it's in my testimony, uh, do have federal funding linked to them. Senator
[1:47:07] Booker. I'm afraid always to get in the way of Senator Kenney when he's got a head of steam going.
[1:47:15] I didn't want to cut you off, sir, but, uh, please hold it, hold it against the chairman and not me,
[1:47:20] okay? Um, this to me is one of the most, uh, important hearings going on right now. I've traveled
[1:47:27] all over the country in my state and, and, and we are in a state of crisis in this country where,
[1:47:33] um, Americans get a prescription and it becomes not a pathway to healing, but a pathway to financial
[1:47:38] ruin. That, that one in four Americans are either not taking their prescription drugs because they
[1:47:44] can't afford them or are, uh, I, I've talked to seniors who cut pills in half. Um, uh, I've talked
[1:47:53] to people who are struggling with mental health and end up having episodes and relapses where they lose
[1:47:59] their jobs and cascade into financial ruin. Um, we are in a, in a, in a national crisis and, and I really
[1:48:06] want to drill in, uh, on, on some of that. So, so Dr. Sood, if I can focus on you, even though you,
[1:48:13] you, you represent the university of Southern California, correct? They have a horrible football
[1:48:18] team. I, I, I did score a touchdown against them. I'd like that into the record, please. Um, uh,
[1:48:25] but beside the university, which is a great university, but their football team is spawned
[1:48:30] from some dark place. Um, uh, but I, I, this is extraordinary to me, uh, is your research shows
[1:48:39] that middlemen take roughly 41 cents of every dollar spent on prescription drugs. I mean,
[1:48:43] nearly half of the money is being taken by middle people, not the prescriber, not the person who
[1:48:52] produces the drug, not, and obviously it's coming out of the patient's pocket. That's outrageous.
[1:48:58] And so I want to know more about who's getting rich off American people getting sick,
[1:49:03] that an illness is suddenly an opportunity to exploit Americans at their most vulnerable moment.
[1:49:09] When a patient walks into a farm and he pays that outrageous price for a life-saving drug,
[1:49:14] how much of that money is going to companies that never invented the drug, never manufactured the
[1:49:18] drug, never actually providing anything for the pain, uh, patient that are providing very little
[1:49:23] value. They're leeching off of Americans' pain and misery. Um, and the, and the evidence really is
[1:49:29] that this is an extraction of wealth, uh, that other countries aren't doing. Can you describe that for
[1:49:34] me quickly? Thank you for, thank you for the question, Senator Booker. Uh, so you're right,
[1:49:39] I did a study where we found that out of, uh, and as a health economist, I really wanted to know the
[1:49:44] answer to this question. Uh, and what we found out is that up of every hundred dollars in spending,
[1:49:51] which the patient or the consumer pays the entire hundred dollars, ultimately the buck stops at the
[1:49:57] patient, $40 went or $41 went to middlemen and about $60 went to pharmaceutical firms. I repeated the
[1:50:06] study a few years later and, and looked at insulin and what was happening in insulin. And what we found
[1:50:11] is that now the middlemen are making more and more and it's not coming at the cost. It's not reducing
[1:50:19] our overall costs. So basically what's happening is they're kind of, uh, taking money from pharmaceutical
[1:50:25] companies and increasing their own profits without changing overall costs. And as I testified that
[1:50:31] because patient cost sharing is based on list prices. So as rebates go up, list prices go up,
[1:50:38] patients end up paying more. So patients are being gouged by a company that has no, I mean,
[1:50:44] Adam Smith would have a heart attack if he saw this manipulation of the market. Uh, um, it is,
[1:50:50] it is outrageous. And so what, what bothers me about this. So that alone would be bad enough
[1:50:55] if people that have nothing to do with production, manufacturing, distribution,
[1:51:01] nothing to do, but take money away from patients, uh, at their lowest points where they're struggling
[1:51:06] with illness, that would be bad enough. But what I, what it really bothers me is that that within this
[1:51:11] system is that it's extraordinary conflicts of interest. The corporations can make more money
[1:51:18] by steering patients towards their own businesses, um, even when cheaper alternatives exists. And,
[1:51:24] and so again, can you just explain really quickly in my final seconds why this is anti really works
[1:51:31] against the free market? It is an exploitation of everything we know about competition, this
[1:51:36] vertical integration. So I, I was one of the few experts who opposed the CVS-Aetna merger, you know,
[1:51:43] more than a decade ago. And, and it's basically because of the conflict of interest. So, uh, PBM's job
[1:51:50] is to negotiate with pharmacies, but if it owns its own pharmacies, it's going to disadvantage other
[1:51:56] pharmacies in the market. Right. And, and I just want to add just because we're seeing the FTC do
[1:52:02] nothing but Kabuki theater. They're not enforcing that they just reached three settlements, right?
[1:52:08] With, with, with two of the three dominant PBMs over these kinds of practices around insulin.
[1:52:14] But those settlements don't break up these conglomerates, don't end the conflict of
[1:52:18] interests in any way. And they expire after 10 years. And so we're simply telling these
[1:52:24] corporations to behave better while leaving intact the very structures that incentivize,
[1:52:29] uh, this kind of exploitation of patients. Isn't that correct?
[1:52:33] That is correct. But we have made progress on transparency with the CAA and the department
[1:52:40] of labor rules. And so my view is, I want to see how this transparency plays out, especially if we
[1:52:46] can add fiduciary responsibility. And if PBMs continue to, you know, take advantage of consumers
[1:52:53] after transparency and fiduciary responsibility, I agree with you, then, then we have no option but to
[1:52:58] break up the vertical, uh, integration in the market. But, but, but it, it isn't how these companies
[1:53:05] behave. It isn't a transparency problem. Ultimately, we need to fix the structure that allows the vertical
[1:53:12] integration. And we've done nothing about that, that, that wouldn't you agree that this is market
[1:53:17] manipulation. This, this, this, this structure is, is broken and we need to break up these vertically
[1:53:23] integrated companies. That's the real solution, isn't it?
[1:53:26] So, as I said, I'm not a fan of vertical integration. I opposed vertical integration over
[1:53:32] a decade ago, but I am a little hesitant, uh, to, to ask these companies to sell off their pharmacies
[1:53:40] wholesale because I'm worried it might be disruptive for patients if a lot of these pharmacies, you know,
[1:53:47] shut down and patients need to travel longer. So what I want to do is give transparency and
[1:53:54] fiduciary responsibility a shot, which is we're going to hold your account.
[1:53:58] I'm over my time. And this is a tough chairman. I just want to say is the reason why pharmacies
[1:54:04] are going out of business is because they exercise an unfair advantage. And we're losing the mom and
[1:54:09] pop pharmacies to these big vertically integrated companies. The system is broken. It is rigged.
[1:54:14] Everybody's extracting money out of it. And patients are suffering as a result of it. And USC's football
[1:54:20] team is awful. Thank you. Before Senator Brett, I want to follow up just a short question of that 41
[1:54:28] cents. How much of it is taken by PBMs if you've got that figure? So this study was done, uh, you know,
[1:54:37] more than 10 years ago. It was about out of every hundred dollars, six dollars went to PBMs at that time.
[1:54:43] Would you assume that at 41 cents, you said the study was 10 years ago. Is that still relevant today?
[1:54:52] Uh, so, so as I said, I, I repeated the study, uh, more recently using data from insulin. And what I
[1:54:59] find there is that what PBMs are taking in has increased three poles, uh, since then. So those old
[1:55:06] results are, are, are not relevant or, you know, slightly less than three poles, two and a half times.
[1:55:11] Wait, you said it, it's increased threefold? Yes. Senator Brett.
[1:55:15] So if you, if you look at the, uh, we published that study in a leading medical journal,
[1:55:20] and what we found is of every hundred dollars on say insulin spending, PBMs used to, you know,
[1:55:26] get four or five dollars and now it's close to $15. I mean, I mean, that's, that is robbery.
[1:55:32] Senator Brett.
[1:55:32] It's stealing from vulnerable people. And I know Senator Brett's going to let you have it now. So buckle up.
[1:55:37] There you go. Thank you. Thank you.
[1:55:39] I actually, I want to, um, just pick up where, where my colleague from New Jersey left off.
[1:55:45] He talked about a number of different things. I want to start by just hearing from,
[1:55:48] from each of you. I know we're, we're clearly at an inflection point. We have to do something when
[1:55:54] it comes to, um, the prescription drug pricing. I know we have done a number of things over the last
[1:56:01] couple of years from the consolidated appropriations act in 2026. You mentioned new DOL rules. Um, we know
[1:56:09] Trump RX, um, Medicare Part D price negotiations. Uh, he mentioned the FTC settlement, um, new PBM
[1:56:17] transparency. So there's some things out there. My question is of, in the last couple of years,
[1:56:23] these different laws or, or movements of those, um, whatever you want to, wherever you want to go with this,
[1:56:30] which ones of these things have actually helped reduce price and then which one of these things
[1:56:37] maybe was well intended, but didn't have the effect that we thought that it would.
[1:56:41] And I'll start with you, Dr. Watson.
[1:56:42] One of the things I want to talk about is the, what we haven't controlled is reimbursement rates
[1:56:48] that do not keep up with the cost of acquiring and dispensing medications.
[1:56:51] Okay.
[1:56:51] When I took over as CEO, I thought we could just open what we we're affiliated with the College of
[1:56:55] Pharmacy. So I thought it'd be easy for us to open up community pharmacies, but that's not the case
[1:56:59] because we are not able to compete financially. Like I said, our pharmacy has lost almost over
[1:57:05] $3 million over the last three years. So one of the things that we got to get better at is ensuring
[1:57:09] that the reimbursement rates for your academic and community and those mom and pop pharmacies,
[1:57:14] particularly in rural areas, that they're able to compete with other big farm, other big pharmacies.
[1:57:19] Because if we don't do that, our patients will be left without access to the drugs that they need
[1:57:24] and prescriptions will go unfulfilled, which is what we've seen.
[1:57:26] Absolutely.
[1:57:29] I would say the laws that have worked in terms of reducing patients' costs are like the insulin
[1:57:36] copay cap or the $2,100 or $2,000 limit on out-of-pocket costs for Medicare Part D. So they help patients
[1:57:44] at the pharmacy counter, but there's a trade-off there that if you just control out-of-pocket costs,
[1:57:50] premiums go up. And we've had to spend $10 billion in Part D to stabilize those premiums.
[1:57:59] What I think hasn't worked as well as I would like it to work is biosimilar competition. So what
[1:58:06] biosimilar competition does is it does lower overall net prices. Branded companies compete with biosimilars
[1:58:14] by giving larger rebates to health plans. But again, patients are paying based on the list price of
[1:58:19] the drug. So even if there's a biosimilar, the health plan will cover the branded drug because
[1:58:25] they're getting a bigger rebate, and patients end up paying more because they're paying based on the
[1:58:29] list price. So having cost sharing based on the actual price of the drug minus the rebates helps
[1:58:37] patients because you're ensuring that that discount goes directly to the patient and not somewhere in
[1:58:43] the middle, not an intermediary. So to me, that would be the biggest policy win if we can have
[1:58:50] patient cost sharing be based on the net price of the drug, not the list price.
[1:58:54] Okay, thank you.
[1:58:55] I agree with my panelists on things that have gone well. One thing that is maybe a double-edged sword,
[1:59:01] intended well, is many states have passed a reimbursement floor for pharmacies plus a dispensing
[1:59:06] fee. Without proper protections, that dispensing fee is often passed on to the patient. So say a
[1:59:10] $10 dispensing fee to cover that pharmacy for overhead, staffing, etc. to dispense that prescription,
[1:59:15] say it's $10, that $10 ends up getting passed to the patient to pay that instead of the health plan or
[1:59:19] PBM. Okay, so I'm of course very biased. But yeah, if you look at my pharmacy's website, our prices are
[1:59:28] lower than you and from any of the big three PBMs. How can that possibly be the case? They're enormous
[1:59:34] compared to us. In fact, for generic drugs, Americans get the best prices in the world behind the scenes.
[1:59:40] Anything else is an additional markup. So I'm with the senator from New Jersey. You've got to break up these
[1:59:46] conglomerates. And you know, Dr. Pitlick, your pharmacies and your network, they can do all of these
[1:59:52] pharmacies, specialty pharmacy services. It's nonsense that your local community pharmacist
[1:59:57] cannot provide you a better standard of care than a giant mail-order specialty pharmacy in the middle
[2:00:04] of nowhere. So as you look into the earnings calls that are coming out this quarter from the big PBMs,
[2:00:11] you see their PBM revenue actually going down. But their specialty pharmacy revenue is skyrocketing.
[2:00:18] It's going up higher than that. So the immediate win, I think, would be to break up pharmacies from the
[2:00:23] PBMs. But the longer term problem, because they're just going to shift it somewhere else,
[2:00:27] for biosimilars, they've set up their own pharmaceutical companies that white label
[2:00:34] the biosimilars so they can mark up the cost. They're going to shift it somewhere else. So
[2:00:37] ultimately, you need to worry about it. And Ms. Pasi. Thank you for your question.
[2:00:43] We've supported the legislation that has already passed that has focused on PBMs and also support
[2:00:51] tackling vertical integration. I think you mentioned what will actually have a real impact on price. And
[2:00:59] I think if we really want to tackle price seriously, we'd need to look at the launch price of medications
[2:01:06] that is set by pharmaceutical corporations independently. Well, there's no doubt we have
[2:01:11] to take a comprehensive approach to this. And we've got to do something. We've got to make sure that our
[2:01:15] rural and independent pharmacies not only survive, but thrive. And we need to make sure that the cost
[2:01:23] savings are passed to the actual consumer. We have to do something now. So I appreciate you holding this
[2:01:28] hearing. And I have some more questions for the record and would love for you all to get back to me
[2:01:32] in detail as we look for a new path forward. Senator Welch. Thank you. Thank you very much.
[2:01:40] It's an incredible panel. And I've been listening and I just want to go over some of the things that
[2:01:47] Senator Kennedy brought up because I think they're really relevant. We have an opportunity now to
[2:01:54] together, Republicans and Democrats, to take a lot of your ideas that would save money for the American
[2:02:02] taxpayer and the American consumer. And I hope we do. But Senator Kennedy said, we need drugs. I agree.
[2:02:08] My first wife had cancer and was an incredible beneficiary. Our family was of life extending and
[2:02:13] pain relieving medications. They're expensive. The private sector is essential. And we do need
[2:02:23] incentives. But what you are identifying are market manipulation efforts that have nothing to do with
[2:02:31] incentives. It has to do with market power and the ability to exploit it. And the effects of it,
[2:02:37] like my colleague, Senator Britt mentioned, among other things are high expense in crushing the local
[2:02:45] pharmacies. And what my hope is, Mr. Chairman, you've been a leader on unfair pricing. My hope is that
[2:02:54] we're going to be able to do some bipartisan legislation that focuses on competition, that takes away
[2:03:03] the manipulation of the patent system. Senator Hawley and I have the ethics act, which would
[2:03:12] essentially get rid of patent thickets. And also calm down a little bit. There's a debate about Medicare
[2:03:20] for all. I mean, I happen to believe that we should have a health care system where everybody, regardless of their
[2:03:26] income, has access to health care. But whatever system we have, if it's taxpayer funded, if it's
[2:03:34] employer sponsored health care, if it's individual pay, everyone's getting hammered. Everyone's getting
[2:03:41] hammered by these high cost of prescription medication. And we pay three times as much or more
[2:03:48] in this country than any other country, even though we're the country that provides most of the research.
[2:03:53] That's just unacceptable. So I'll speak to my Republican colleagues. I want to work with you
[2:03:59] because the beneficiaries of things that we can do to lower price are going to be shared by all of
[2:04:07] the people we represent, Republicans, Democrats, and Dependents. I'll just ask a little bit about the
[2:04:14] patent thickets, because I am working on that with Senator Hawley. And Ms. Basie, could you talk a little
[2:04:24] bit about that? You know, you have a patent system. I support a patent system. It gives exclusivity
[2:04:32] and rewards innovation. But the thicket system means that the patent system is just rampantly abused
[2:04:41] for self gain and beyond what the purpose of patent system is. Could you talk a little bit about that?
[2:04:47] So the patent system was designed to incentivize genuine innovation, novel treatments that save lives.
[2:04:54] Right now, the patent system isn't just incentivizing innovation. It's incentivizing manipulation.
[2:05:05] And that is the subject of these bills. What patent thickets are, a drug company can file multiple
[2:05:14] duplicative, non-obvious, non-innovative patents on a single drug. And even if they expire at the same time,
[2:05:24] they create a thicket, which makes it much harder for a generic or biosimilar competitor to enter the
[2:05:31] market. So just as a matter of principle, if you have one invention, does it make sense to have one
[2:05:35] patent? For the, the simple answer is yes. But I think on the key elements that are truly innovative,
[2:05:45] right, the system should reward those. But there's an example with a drug called Simbravo. And there's
[2:05:51] two patents in particular of the 90 something that it has. One of them is for pain relief. And one is
[2:05:59] for pain freedom. Right. Now that is not the type of innovation that patients in our community are
[2:06:05] seeking. That's a verbal manipulation. Yeah. And it's mocking. Let me move on. I want to thank you
[2:06:10] very much. You know, I'm amazed, Mr. Ajmayansky, I hope I pronounced that right, what you guys do.
[2:06:17] We've got to put you in charge. I mean, how do you manage to get the price down compared to what the
[2:06:24] rest of us have to pay? Yeah, so that's Medicare and Medicaid. Oh, so thank you. That's very kind.
[2:06:30] I will say, you know, one of the big misconceptions about us is that we drive the price lower from
[2:06:35] pharmaceutical companies. We actually pay more than the big, than the big purchasers because we're a
[2:06:42] small company. The pharmaceutical companies like working with us because we pay a little bit more for
[2:06:47] the cost of the drugs. And there's more money for research and development left over.
[2:06:51] The massive savings comes from, at the expense of the intermediaries in the supply chain. So,
[2:06:57] you know, to some extent, again, very much appreciated, but actually we're not as good
[2:07:02] of negotiators. We just are honest about the prices. You know, Mr. Thank you very much. You know,
[2:07:07] Mr. Chairman, my time is up, but I just, we've got a reset opportunity here. And
[2:07:12] this is not at all a Republican Democratic deal. I mean, we've got people who've been working on this
[2:07:18] forever. They're very practical. Nobody who is on this panel is anything but supportive of the benefits
[2:07:24] of good medication. They're all in favor of making that accessible and essentially not by taking away
[2:07:32] the incentive, but by taking away the ripoff. So my hope is that we could work together to incorporate
[2:07:38] the ideas that have been presented here by this panel to benefit all the people we represent,
[2:07:43] including in your wonderful state of Iowa and my state of Vermont. Thank you.
[2:07:48] I agree with you. In addition to what they've suggested we should do, don't forget, we've already
[2:07:54] voted out six bills out of this committee that would save drug prices. I don't know what's holding
[2:07:59] the five that we haven't got passed on the United States Senate.
[2:08:02] I am with you and we're United States senators and let's get those pieces of legislation moving.
[2:08:08] Okay. Senator Moody.
[2:08:10] I was going to point that out, Mr. Chairman, that out of this committee,
[2:08:14] with your leadership, we've passed out six bipartisan prescription drug competition bills
[2:08:19] by voice vote. And so these should be bills that should be taken up by the floor and we should get
[2:08:24] moving. I think I have been one of the major antagonists to getting things moving and I will keep
[2:08:29] doing that. I appreciate all the witnesses being here today. Generally speaking, we will have minority
[2:08:34] and majority witnesses. All of you are consensus witnesses today. I think that speaks volumes for
[2:08:39] what we're trying to achieve. Consumers benefit, Americans benefit if we can ensure that we protect
[2:08:49] free, fair, competitive markets without conflicts of interest, without any rigging. And what's happened
[2:09:00] is I think legislation over time and markets over time have now developed into a structure that
[2:09:08] prevents transparency of pricing and is very opaque and things get, and this isn't just regarding
[2:09:16] prescription drugs. This is hospital pricing. This is health care pricing, right? And I think the
[2:09:22] reaction by Americans in general, they're like, what is happening? So much of my budget is now going to
[2:09:27] health care. I can't keep this up. They throw up their hands when we don't respond and say just let
[2:09:34] government take over everything. Give it all to government. Let government have control. Let government
[2:09:40] seize the private market. We see this happened in health care. They're demanding more and more that
[2:09:46] government just take over private health care because it's gotten so expensive and it's so opaque in
[2:09:52] the pricing and we can't withstand this. That is insane. What we need to be doing as government,
[2:09:59] which is to protect individuals and freedom, is saying what can we be doing to protect and make more
[2:10:06] transparent and competitive these free markets, not throw up our hands and lend credibility to the
[2:10:13] lunacy of government should control everything and that's going to make everything cheaper and better. That
[2:10:19] is insane. Prices have skyrocketed as government has gotten more and more and more in control of the private
[2:10:26] markets and health care. What we need to be doing is taking action to make it more free, competitive
[2:10:31] and transparent and I'm glad that's kind of where these discussions have been going. I'm glad that's
[2:10:37] where we're focused. I will not give credence to governments to control things because give me any
[2:10:42] other nation state where they've tried that and it leads to just red lines, blackouts and oppression of
[2:10:50] people. Like in America we stand up for protecting freedom and free markets and that's where we need to focus
[2:10:55] these things. But it's true Americans are struggling to afford their prescription medications and
[2:11:01] because of the market that we have allowed to develop which shields pricing transparency and competitiveness.
[2:11:11] In fact I think the three largest PBMs process nearly 80 percent of all prescription claims in 2025.
[2:11:17] That shows a dominance of just a handful of companies. The prescription drug market seems to be captured.
[2:11:27] In Florida we have put forth common sense legislation called the Prescription Drug Reform Act which tries to
[2:11:37] bring transparency to the market which I think is important and we are seeing results from that
[2:11:44] meaningful enforcement, accountability and we see that there can be alternatives built around transparency
[2:11:52] and competition and putting patients first. And I really liked the fact that this administration
[2:11:58] thought outside the box and set up TrumpRx. How can we get prescription drugs directly to consumers?
[2:12:04] Again going back to how I started promoting free markets, taking out the opaque nature of pricing and
[2:12:13] letting consumers decide. And in fact TrumpRx has resulted in so many drugs being offered at a low cost to
[2:12:22] Americans. I just have to say they've added more generic medications. I'll just give you an example.
[2:12:30] A blood thinner 98 percent cheaper, glaucoma eye drops 95 percent cheaper, multiple sclerosis treatment 93 percent
[2:12:39] cheaper. I love that Cost Plus Drugs has worked with TrumpRx to make sure that we can add more and more
[2:12:50] drugs to this exchange again because we're getting back to how can government protect and make available
[2:12:56] more competitive free markets. And I just want to turn to you Mr. Oshmianski and don't think I didn't
[2:13:01] notice every time we were talking about freer more competitive markets you were shaking your head.
[2:13:06] Yes, and I am a big believer in that. Can you just tell us how Cost Plus Drugs partnership with
[2:13:11] TrumpRx works and how that initiative is helping more Americans find affordable prescription medications?
[2:13:17] Yeah, exactly. You know it's a nuanced answer between what role does government play,
[2:13:23] what role does private sector play, but yeah certainly cutting out the negotiating intermediaries
[2:13:28] like TrumpRx did. You know cards on the table I tend to share my co-founder's politics,
[2:13:34] but credit where credit's due with TrumpRx. It did great things with fertility drug pricing
[2:13:39] specifically. It got those prices down because you took out the negotiators who are not negotiating
[2:13:44] as fiduciaries for their members and negotiated better prices directly for American people. Why
[2:13:50] don't we do more of that? And Cost Plus is a vendor into TrumpRx. We're very proud of that work.
[2:13:56] I think it got us, GoodRx, Amazon all together, and now you can shop around to all of us for the best
[2:14:01] price. You know, if our price isn't as good as Amazon's price. Never happens, but you know,
[2:14:06] for the sake of argument, you know, you can go to the best price there through the exchange. So
[2:14:10] the more that that government interacts with the free market in that way, the better.
[2:14:15] Thank you, Mr. Chairman. Sorry to go a little over.
[2:14:19] Senator Klobuchar and Senator Hawley, I'm going to step out for a few minutes,
[2:14:24] but I'll be back before you're done.
[2:14:26] Thank you. Thank you, Mr. Chairman. And I really appreciated the work we've done together on
[2:14:31] prescription drugs. I'm going to miss asking questions about patent thickets and shams and
[2:14:39] various things that I hope we can get done, if not the end of this year, going into next year.
[2:14:44] I did want to take a moment to recognize David Mitchell, the founder of Patients for Affordable
[2:14:50] Drugs. He passed away from cancer, as we know, in January after 15 years of a fight. And when he got
[2:14:58] his diagnosis, he didn't despair. He used his time to advocate for affordable drugs. And as
[2:15:04] one of the leaders on the Medicare negotiation bill, something I'm proud of, I would have added
[2:15:09] more drugs, obviously. I don't know that we would have been able to get it done without his persistence,
[2:15:15] as well as many others. So I guess I would start with that question about Ms. Basie on the
[2:15:23] Medicare negotiation bill, how it would be helpful to add more drugs and add them more quickly to the
[2:15:31] list of drugs being negotiated. Thank you for your question. And thank you for recognizing David.
[2:15:38] And we keep his story in mind in this fight. Adding more drugs would benefit more patients
[2:15:46] more quickly. We need more competition. These drugs are drugs that don't have competition on the
[2:15:51] marketplace because of some of the tactics that we've described today. So increasing the number
[2:15:57] of expensive drugs without generic competition for negotiation would benefit many more millions of
[2:16:04] people who are tired of paying high prices. Okay, very good. Thank you. Mr. Oshmionski,
[2:16:13] your company Cost Plus offers nearly 2,500 generic drugs to patients. These alternatives would not be
[2:16:22] available if branded drug manufacturers were allowed to further extend their monopoly over drugs.
[2:16:27] How does ensuring branded drug manufacturers do not improperly extend their patent monopoly
[2:16:34] help Cost Plus get those medicines into the hands of patients at an affordable cost?
[2:16:40] No, absolutely. Yeah, we're absolutely opposed to patent thickets. It's, you know, bad practice all
[2:16:48] around. We don't go after that as sort of the core issue driving high drug prices, but it's definitely an
[2:16:53] issue that should be addressed. And the more drugs go biosimilar, the more drugs go generic, the more we can
[2:16:59] pass along the true cost of those drugs. Exactly. I know there was some discussion about ways to potentially
[2:17:05] move forward biosimilar development more quickly. I think anything that allows the FDA to use a quality
[2:17:11] target profile and analytic testing for measuring the similarity of a biosimilar to its innovator product,
[2:17:19] as opposed to repetitive clinical trials, taking a measured risk-based approach, I think, would help a
[2:17:26] lot. It's particularly as we're facing this biosimilar void. Sure, I agree. I'm going to just do a lightning round
[2:17:34] using my own selfish interest of what states can do for my upcoming role. I, of course,
[2:17:40] am focused on biosimilars and getting more competition, but also using possibly bulk purchasing power
[2:17:49] to try to make it easier on a state basis, knowing that a lot of this work also has to be done federally.
[2:17:56] So just a lightning round of ideas of what states, what you think could be some good things states
[2:18:02] could do to bring down the cost of prescription drugs. Anyone want to start? Just very briefly,
[2:18:09] like a few sentences. I've been trying to talk states into a multi-state drug purchasing coalition.
[2:18:13] That's what I was, and Minnesota is actually part of the, it leads the biggest one. So it has some real
[2:18:20] potential. Okay. Yes. Thank you. The question center, anti-steering would be my choice. Okay.
[2:18:28] Basing a patient cost sharing on the net price of a drug rather than the list price of the drug.
[2:18:34] Mm-hmm. Very good.
[2:18:35] Protecting community and academic pharmacies from closing in some of our, and
[2:18:39] preventing the pharmacy deserts from worse. Exactly. Thank you. And Ms. Basie?
[2:18:44] And we focus primarily on the, at the federal level, but have been involved with supporting
[2:18:50] the Prescription Drug Affordability Boards as part of the process.
[2:18:53] Mm-hmm. Yes. Okay. Very good. Well, thank you, all of you, and look forward to hearing about all the,
[2:19:00] I hope, some of the progress we can make, especially on these bipartisan bills that are, have been sitting
[2:19:06] around for quite a while now, and we'd like to get them done. Thank you.
[2:19:10] Thank you, Senator Colbertron. Senator, go ahead.
[2:19:14] Thank you very much, Mr. Chairman. Thanks to the witnesses for being here. I think at this point,
[2:19:22] we can stop talking about whether or not healthcare is getting less affordable, and start asking
[2:19:29] ourselves if it's just getting outright impossible to access healthcare in this country at all. I want
[2:19:34] to show you a chart that I'm sure that you, the panelists, are familiar with. Health expenditures between
[2:19:39] 1960 and 2024. Here's the delta. Adjusted for inflation, this is a 2,345% increase in health
[2:19:49] expenditure since 1960. This is inflation-adjusted, I emphasize. 2,345% increase. For retail prescription
[2:19:58] drugs, it's just as bad. 2,093% more today. We spend 2,093% more today on retail pharma than we did in
[2:20:10] 1960. I mean, it's absolutely astounding. And in my state, home state of Missouri, it's just totally
[2:20:17] unaffordable. I mean, right now, one recent report analyzed that spending between 1929 and 2024 concluded
[2:20:24] that we spend more on healthcare today than people spent on groceries or housing. I mean,
[2:20:32] that is absolutely unbelievable. And in the state of Missouri, when it comes to independent pharmacies,
[2:20:39] in 2023 alone, Missouri lost 73 independent pharmacies across 19 counties. 73 independent pharmacies.
[2:20:48] We now have two entire counties in the state of Missouri that have
[2:20:51] no pharmacies. Zero in the entire county. A month ago, a small rural hospital in Houston,
[2:20:59] Missouri closed its retail pharmacy due to financial hardship. And that has become the
[2:21:04] norm in my state and around the United States. Between 2010 and 2021 nationwide, there were more
[2:21:10] than 26,000 retail pharmacy locations closed. That was nearly a third of them nationwide. I mean,
[2:21:18] that's unbelievable. In 10 years, we lose a third of the retail pharmacies. And in my state, we're losing
[2:21:23] them by droves. Mr. Oshmoyensky, I just want to start with you, Dr. Oshmoyensky. Don't let me downgrade
[2:21:29] you there. Let me, first of all, just say that I'm glad you're here. Your company, I think,
[2:21:34] and your business model is really very interesting and presents a hopeful picture of what we might see
[2:21:40] going forward. And you know, the problem of high drug prices and how precarious our supply chain is.
[2:21:46] Let me just ask you to start with, I want to ask you about this recent news about CVS.
[2:21:51] CVS announced it would separate its behemoth of a business, which includes an insurer, a PBM,
[2:21:58] a manufacturer, as well as specialty and retail pharmacies. They announced a couple of weeks ago
[2:22:02] that they're going to separate those into two publicly traded companies. They took credit and said,
[2:22:09] well, this is going to be great for consumers. This is going to save consumers money. This is very
[2:22:13] positive and consumer facing. Let me just ask you, I mean, should Americans believe CVS and the C-suite
[2:22:20] when they say that they're spinning off their pharmacies to, let me quote them, make healthcare
[2:22:24] more affordable, more accessible, and simpler to navigate? Well, my bias is on the table, but short
[2:22:31] answer, no, of course not. You know, all credit to you and Senator Warren for your bipartisan legislation.
[2:22:37] I think that's pushing entities like CVS towards these divestiture actions. But importantly, CVS
[2:22:45] specialty pharmacy, which is where they make the, which is far more profitable than CVS retail pharmacy,
[2:22:51] is staying with the core entity. And that is keeping all of the profitable prescriptions that should
[2:22:57] otherwise be going to pharmacies like in Dr. Pitlick's community. So, and you know, we haven't even gotten to
[2:23:04] touch yet on the wholesale distributors. And what CVS, to my knowledge, did not divest was Red Oak.
[2:23:11] It's a source program that purchases all of these programs wholesale in combination with the drug
[2:23:17] wholesalers and transacts everything at a whole, at a higher price. In every wholesaler, in every industry,
[2:23:25] you, the wholesaler buys a product, they mark it up a little bit, they resell it.
[2:23:29] Unique in pharmaceuticals, they buy it at an artificially inflated list price,
[2:23:33] and they discount it to the pharmacies, which means they're getting paid in other ways on the
[2:23:39] back end, while keeping up generic compliance ratios, which force pharmacies to purchase drugs
[2:23:46] at elevated costs. Sorry. Let me do, let me just, well, this is terrific. Let me just, before my time
[2:23:50] runs out, let me just ask you this. Since you mentioned the Breakup Big Medicine Act, which Senator
[2:23:54] Warren and I have together, which I think is a tremendous piece of legislation, it would prohibit
[2:23:58] a parent company from owning both a medical provider and a PBM or an insurer. I mean, it would,
[2:24:03] it would do just what the title says. It would bring some competition back to the medical supply
[2:24:08] chain and prohibit these massive insurers and PBMs from controlling the entire supply chain top to
[2:24:13] bottom. Why do you think that that's so important? Your whole business model, as I understand it,
[2:24:17] is built on cutting out the middleman. Why is it important that we break up these huge behemoths that
[2:24:22] are squeezing not just the supply chain, they're squeezing consumers, they're squeezing patients who can't see
[2:24:27] doctors who can't afford their health care, who can't afford prescription drugs?
[2:24:30] No, I think it's definitely where the industry is moving where they want to shift dollars to
[2:24:34] is providers that they themselves own. There's a reason the big pharmaceutical wholesalers are buying
[2:24:41] physician practices because they can tell them what to prescribe and they can tell them to prescribe
[2:24:46] the more profitable drugs. Yeah, if you're buying a Toyota Corolla and a negotiator comes in and says,
[2:24:53] I got you 90% off the cost of your car, and then you learn that the list price of the Corolla is a
[2:24:59] million dollars, you're not going to be happy with that deal. But that's the deal all Americans get at
[2:25:04] the moment. I'll just end with this, Mr. Chairman. I think that what we are seeing, what American
[2:25:08] patients are seeing, is a massive consolidation of industry where you've got two or three insurance
[2:25:14] companies working in concert with PBMs, buying up hospitals, buying up pharmacies and then closing them
[2:25:20] down, buying up doctor's practices. And now Americans, they can't get an appointment at the
[2:25:24] doctor. They can't afford the doctor's visit when they finally get there. They can't afford any of
[2:25:29] the prescriptions that the doctor may give to them. It is absolutely outrageous. In this,
[2:25:33] the most prosperous country in the world, basic affordability of health care is simply not there.
[2:25:39] I mean, Americans can't afford to take their kids to the doctor and somebody's getting rich off of it.
[2:25:43] And the people who are getting rich are the insurance companies and these other massive
[2:25:46] conglomerates that are rolling up the whole supply chain. We need to break them up. We need more
[2:25:51] competition. We need to put power back in the hands of consumers. And I hope legislation like the
[2:25:56] Breakup Big Medicine Act is something that we can take up in this committee, Mr. Chairman,
[2:26:00] and on the floor next Congress. Thank you all for being here. Thanks for your work in this important area.
[2:26:04] In addition to what you said about PBMs, nobody knows what they negotiate and it all ought to be
[2:26:11] transparent. With transparency comes accountability. Well, listen, before I let you go and say thank you
[2:26:18] to you, I probably got a couple rebuttals here that I should have done when I'm responding to
[2:26:25] some of my colleagues, but I'll go ahead and do it anyway. In regard to Medicare for All,
[2:26:32] one estimate says that Medicare for All would cost $44 trillion in the first 10 years.
[2:26:38] And that cost is something that we can't afford. Medicare for All would, of course,
[2:26:46] eliminate compensation and drive up costs. And then a rebuttal to Senator Kennedy. I appreciate
[2:26:55] Senator Kennedy's frustration that he expressed. To set the record straight, this committee has marked up
[2:27:02] six bills that will lower drug costs. Almost everybody on this committee has talked about
[2:27:11] the six bills that were voted out of this committee on a voice vote, which means they were unanimously
[2:27:17] approved. This concludes today's hearing. Senator Durbin and I, along with the entire committee, thank
[2:27:25] each of you of our witnesses for being here today and for your testimony. Today's discussion will help
[2:27:34] us continue bipartisan work to increase transparency and competition, preserve patient access, and ensure
[2:27:41] prescription drug savings reach our patients. I ask unanimous consent to enter into the record any
[2:27:50] statements, statements, letters, or other materials submitted to the committee in connection with this,
[2:27:55] today's hearing. And without objection, that would be so ordered. For you folks that are witnesses,
[2:28:04] written questions may be submitted for the record for one week from now. I ask each of you to return
[2:28:12] their answers to the committee within two weeks after receiving the questions. Thank you very much.
[2:28:19] And the hearing is adjourned.